ZA200300900B

ZA200300900B - Novel aminocyclohexane derivatives.

Info

Publication number: ZA200300900B
Application number: ZA200300900A
Authority: ZA
Inventors: Jean Ackermann; Denise Blum; Henrietta Dehmlow; Olivier Morand; Elisabeth Von Der Mark; Thomas Weller; Johannes Aebi; Alexander Chucholowski; Hans-Peter Maerki; Rene Trussardi; Sabine Wallbaum
Original assignee: Hoffmann La Roche
Priority date: 2000-08-16
Filing date: 2003-01-31
Publication date: 2004-04-30
Also published as: CN1338580A; ECSP034482A; GT200100166A; CN1156648C

Description

‘ Novel Aminocyclohexane Derivatives . The present invention is concerned with novel aminocyclohexanol derivatives, their manufacture and their use as medicaments. In particular, the invention relates to compounds of the formula (I)

I

3 4 Nw-a® 1 A A V

AN > PAN uY (CH) (CH), M

A wherein

U is O or a lone pair, \% is 0, S, -CH»-, -CH=CH-, or -C=C-,

Ww is CO, COO, CONR', CSO, CSNR', SO,, or SO;:NR', mand n independently from each other are 0 to 7 and m+n is 0 to 7, with the proviso thatmisnot0ifVisOorS,

Al is H, lower-alkyl, hydroxy-lower-alkyl, or lower-alkenyl, :

A? is lower-alkyl, cycloalkyl, cycloalkyl-lower-alkyl, or lower-alkenyl, optionally substituted by R?,

A’and A* are hydrogen or lower-alkyl, or

Aland A’ or A' and A’ are bonded to each other to form a ring and - A'- A%- or - A'- A’ are lower-alkylene or lower-alkenylene, optionally substituted by R%, in which one -CH,- group of -A'- A> or -A'-A’- can ) optionally be replaced by NR?, S, or O, or ‘ A’ and A* are bonded to each other to form a ring together with the carbon atom to which they are attached and -A’-A*- is -(CH,)2.s- which can optionally be mono- or multiply-substituted by lower-alkyl,

A® is H, lower-alkyl, lower-alkenyl, or aryl-lower-alkyl,

AS is lower-alkyl, cycloalkyl, aryl, aryl-lower-alkyl, heteroaryl, heteroaryl-lower- , alkyl, lower-alkoxy-carbonyl-lower-alkyl,

R? is hydroxy, hydroxy-lower-alkyl, lower-alkoxy, lower-alkoxycarbonyl, ‘ 5 N(R R?), or thio-lower-alkoxy,

R', R’, R* and R’ independently from each other are hydrogen or lower-alky], and pharmaceutically acceptable salts and/or pharmaceutically acceptable esters thereof.

The compounds of the present invention inhibit 2,3-oxidosqualene-lanosterol cyclase (EC 5.4.99.) which is required for the biosynthesis of cholesterol, ergosterol and other sterols. Causal risk factors that directly promote the development of coronary and peripheral atherosclerosis include elevated low-density lipoprotein cholesterol (LDL-C), low high-density lipoprotein cholesterol (HDL-C), hypertension, cigarette smoking and diabetes mellitus. Other synergistic risk factors include elevated concentrations of triglyceride (TG)-rich lipoproteins, small, dense low-density lipoprotein particles, lipoprotein (a) (Lp(a)), and homocysteine. Predisposing risk factors modify the causal or conditional risk factors and thus affect atherogenesis indirectly. The predisposing risk factors are obesity, physical inactivity, family history of premature CVD, and male sex. The strong connection between coronary heart disease (CHD) and high LDL-C levels in plasma, and the therapeutic advantage of lowering elevated LDL-C levels are now well established (Gotto et al., Circulation 81, 1990, 1721-1733; Stein et al., Nutr. Metab.

Cardiovasc. Dis. 2, 1992, 113-156; Illingworth, Med. Clin. North. Am. 84, 2000, 23-42).

Cholesterol-rich, sometimes unstable, atherosclerotic plaques lead to the occlusion of blood vessels resulting in an ischemia or an infarct. Studies with respect to primary prophylaxis have shown that a lowering of plasma LDL-C levels in plasma reduces the frequency of non-fatal incidences of CHD, while the overall morbidity remains unchanged. The lowering of plasma LDL-C levels in patients with pre-established CHD (secondary intervention) reduces CHD mortality and morbidity; meta-analysis of different studies shows that this decrease is proportional to the reduction of the LDL-C (Ross et al.,

Arch. Intern. Med. 159, 1999, 1793-1802). :

The clinical advantage of cholesterol lowering is greater for patients with pre- : . established CHD than for asymptomatic persons with hypercholesterolemia. According to current guidelines, cholesterol lowering treatment is recommended for patients who had survived a myocardial infarct or patients suffering from angina pectoris or another atherosclerotic disease, with a target LDL-C level of 100 mg/dl.

Preparations such as bile acid sequestrants, fibrates, nicotinic acid, probucol as well as statins, i.e. HMG-Co-A reductase inhibitors such as simvastatin and atorvastatin, are used for usual standard therapies. The best statins reduce plasma LDL-C effectively by at oo least 40%, and also plasma triglycerides, a synergistic risk factor, but less effectively. In contrast, fibrates reduce plasma triglycerides effectively, but not LDL-C. Combination of a ' statin and a fibrate proved to be very efficacious in lowering LDL-C and triglycerides (Ellen and McPherson, J. Cardiol. 81, 1998, 60B-65B), but safety of such a combination remains an issue (Shepherd, Eur. Heart J. 16, 1995, 5-13). A single drug with a mixed profile combining effective lowering of both LDL-C and triglycerides would provide additional clinical benefit to asymptomatic and symptomatic patients.

In humans, statins are well tolerated at standard dosage, but reductions in non-sterol intermediates in the cholesterol synthesis pathway, such as isoprenoids and coenzyme Q, may be associated with adverse clinical events at high doses (Davignon et al., Can. J.

Cardiol. 8, 1992, 843-864; Pederson and Tobert, Drug Safety 14, 1996, 11-24).

This has stimulated the search for, and development of compounds that inhibit cholesterol biosynthesis, yet act distal to the synthesis of these important, non-sterol intermediates. 2,3-oxidosqualene:lanosterol cyclase (OSC), a microsomal enzyme, represents a unique target for a cholesterol-lowering drug (Morand et al,, J. Lipid Res., 38, 1997, 373-390; Mark et al., J. Lipid Res. 37, 1996, 148-158). OSC is downstream of farnesyl-pyrophosphate, beyond the synthesis of isoprenoids and coenzyme Q. In hamsters, pharmacologically active doses of an OSC inhibitor showed no adverse side- effects, in contrast to a statin which reduced food-intake and body weight, and increased plasma bilirubin, liver weight and liver triglyceride content (Morand et al., J. Lipid Res., 38, 1997, 373-390). The compounds described in European Patent Application No. 636 367, which inhibit OSC and which lower the total cholesterol in plasma, belong to these substances.

OSC inhibition does not trigger the overexpression of HMGR because of an indirect, negative feed-back regulatory mechanism involving the production of 24(S),25- epoxycholesterol (Peffley et al., Biochem. Pharmacol. 56, 1998, 439-449; Nelson et al, J.

Biol. Chem. 256, 1981, 1067-1068; Spencer et al., J. Biol. Chem. 260, 1985, 13391-13394; ’ Panini et al., J. Lipid Res. 27, 1986, 1190-1204; Ness et al., Arch. Biochem. Biophys. 308, 1994, 420-425). This negative feed-back regulatory mechanism is fundamental to the . concept of OSC inhibition because (i) it potentiates synergistically the primary inhibitory effect with an indirect down-regulation of HMGR, and (ii) it prevents the massive accumulation of the precursor monooxidosqualene in the liver. In addition, 24(S),25- epoxycholesterol was found to be one of the most potent agonists of the nuclear receptor

LXR (Janowski et al., Proc. Natl. Acad. Sci. USA, 96, 1999, 266-271). Considering that

24(S),25-epoxycholesterol is a by-product of inhibition of OSC it is hypothesized that the

OSC inhibitors of the present invention could also indirectly activate LXR-dependent pathways such as (i) cholesterol-7alpha-hydroxylase to increase the consumption of ) cholesterol via the bile acid route, (ii) expression of ABC proteins with the potential to stimulate reverse cholesterol transport and increase plasma HDL-C levels (Venkateswaran ‘ et al., J. Biol. Chem. 275, 2000, 14700-14707; Costet et al., J. Biol. Chem. June 2000, in press; Ordovas, Nutr Rev 58, 2000, 76-79, Schmitz and Kaminsky, Front Biosci 6, 2001,

D505-D514), and/or inhibit intestinal cholesterol absorption (Mangelsdorf, XIIth

International Symposium on Atherosclerosis, Stockholm, June 2000). In addition, possible cross talks between fatty acid and cholesterol metabolism mediated by liver LXR have been hypothesized (Tobin et al., Mol. Endocrinol. 14, 2000, 741-752).

The present compounds of formula I inhibit OSC and therefore also inhibit the biosynthesis of cholesterol, ergosterol and other sterols, and reduce the plasma cholesterol levels. They can therefore be used in the therapy and prophylaxis of hypercholesterolemia, hyperlipemia, arteriosclerosis and vascular diseases in general. Furthermore, they can be used in the therapy and/or prevention of mycoses, parasite infections, gallstones, cholestatic liver disorders, tumors and hyperproliferative disorders, e.g. hyperproliferative skin and vascular disorders. In addition, it has unexpectedly been found that the compounds of the present invention can also be of therapeutical use to improve glucose tolerance in order to treat and/or prevent related diseases such as diabetes. The compounds of the present invention further exhibit improved pharmacological properties compared to known compounds.

Unless otherwise indicated the following definitions are set forth to illustrate and define the meaning and scope of the various terms used to describe the invention herein.

In this specification the term “lower” is used to mean a group consisting of one to seven, preferably of one to four carbon atom(s).

The term "lone pair" refers to an unbound electron pair, in particular to the unbound electron pair of a nitrogen atom in e.g. an amine.

The term “halogen” refers to fluorine, chlorine, bromine and iodine, with chlorine and bromine being preferred. : The term “alkyl”, alone or in combination with other groups, refers to a branched or straight-chain monovalent saturated aliphatic hydrocarbon radical of one to twenty carbon atoms, preferably one to sixteen carbon atoms. Alkyl groups can optionally be substituted e.g. with halogen, CN, NO, carboxy, and/or phenyl. Other, more preferred subsituents are hydroxy, lower-alkoxy, NH,, N(lower-alkyl),, and/or lower-alkoxy-

carbonyl.

The term “lower-alkyl” , alone or in combination with other groups, refers to a . branched or straight-chain monovalent alkyl radical of one to seven carbon atoms, preferably one to four carbon atoms. This term is further exemplified by such radicals as , 5 methyl, ethyl, n-propyl, isopropyl, n-butyl, s-butyl, t-butyl and the like. A lower-alkyl group may have a substitution pattern as described earlier in connection with the term "alkyl".

The term “cycloalkyl” refers to a monovalent carbocyclic radical of 3 to 10 carbon atom(s), preferably 3 to 6 carbon atoms. Cycloalkyl in which one or more -CHS- group is replaced by O, S, NH or N(lower-alkyl) are referred to as "heterocycloalkyl".

The term “alkoxy“ refers to the group R’-O-, wherein R’ is an alkyl. The term "lower- alkoxy" refers to the group R’-O-, wherein R’ is a lower-alkyl. The term “thio-alkoxy“ refers to the group R’-S-, wherein R’ is an alkyl. The term "thio-lower-alkoxy" refers to the group R’-S-, wherein R’ is a lower-alkyl.

The term “alkenyl”, alone or in combination with other groups, stands for a straight- chain or branched hydrocarbon residue comprising an olefinic bond and up to 20, preferably up to 16 carbon atoms. The term "lower-alkenyl" refers to a straight-chain or branched hydrocarbon residue comprising an olefinic bond and up to 7, preferably up to 4 carbon atoms, such as e.g. 2-propenyl. An alkenyl or lower-alkenyl group may have a substitution pattern as described earlier in connection with the term "alkyl".

The term "alkylene" refers to a straight chain or branched divalent saturated aliphatic hydrocarbon group of 1 to 20 carbon atoms, preferably 1 to 16 carbon atoms. The term "lower-alkylene" refers to a straight chain or branched divalent saturated aliphatic hydrocarbon group of 1 to 7, preferably 2 to 4 carbon atoms. An alkylene or lower- alkylene group may have a substitution pattern as described earlier in connection with the term "alkyl".

The term "alkenylene" refers to a straight chain or branched divalent hydrocarbon group comprising an olefinic bond and up to 20 carbon atoms, preferably up to 16.carbon ‘ atoms. The term "lower-alkenylene" refers to a straight chain or branched divalent hydrocarbon group comprising an olefinic bond and up to 7, preferably up to 4 C-atoms. : An alkenylene or lower-alkenylene group may have a substitution pattern as described earlier in connection with the term "alkyl".

The term "aryl" relates to the phenyl or naphthyl group which can optionally be mono- or multiply-substituted by lower-alkyl, lower-alkyl-di-oxo, halogen, hydroxy,

cyano, CFs, NH,, N(lower-alkyl),, aminocarbonyl, carboxy, nitro, lower-alkoxy, lower- alkylcarbonyl, lower-alkylcarbonyloxy, aryl, aryloxy, or lower-alkylcarbonyl-amino, preferably by lower-alkyl, lower-alkyl-di-oxo, halogen, hydroxy, cyano, CFs, NH,, ’ N(lower-alkyl),, aminocarbonyl, carboxy, nitro, lower-alkoxy, lower-alkylcarbonyl, lower- alkylcarbonyloxy, aryl, or aryloxy. Preferred substituents are lower-alkyl, lower alkoxy, ' lower-alkyl-carbonyl, lower-alkoxycarbonyl, fluorine, chlorine, bromine, CN, CFs, NO,

NH,, and/or N(lower-alkyl),. More preferred substituents are fluorine, chlorine, bromine and CFs.

The term "heteroaryl" refers to an aromatic 5- or 6-membered ring which can comprise 1, 2 or 3 atoms selected from nitrogen, oxygen and/or sulphur such as furyl, pyridyl, 1,2-, 1,3- and 1,4-diazinyl, thienyl, isoxazolyl, oxazolyl, imidazolyl, or pyrrolyl.

The term "heteroaryl" further refers to bicyclic aromatic groups comprising two 5- or 6- membered rings, in which one or both rings can contain 1, 2 or 3 atoms selected from nitrogen, oxygen or sulphur such as e,g, indol or chinolin, or partially hydrogenated bicyclic aromatic groups such as e.g. indolinyl. A heteroaryl group may have a substitution pattern as described earlier in connection with the term "aryl".

The term "pharmaceutically acceptable salts" embraces salts of the compounds of formula (I) with inorganic or organic acids such as hydrochloric acid, hydrobromic acid, nitric acid, sulphuric acid, phosphoric acid, citric acid, formic acid, maleic acid, acetic acid, fumaric acid, succinic acid, tartaric acid, methanesulphonic acid, p-toluenesulphonic acid and the like, which are non toxic to living organisms. Preferred salts are formates, hydrochlorides and hydrobromides.

The term "pharmaceutically acceptable esters” embraces esters of the compounds of formula (I), in which hydroxy groups have been converted to the corresponding esters with inorganic or organic acids such as, nitric acid, sulphuric acid, phosphoric acid, citric acid, formic acid, maleic acid, acetic acid, succinic acid, tartaric acid, methanesulphonic acid, p-toluenesulphonic acid and the like, which are non toxic to living organisms.

In detail, the present invention relates to compounds of formula (I)

A” a2 At JO all > A oY, CHI, (Ch 0

A wherein

U is O or a lone pair,

Vv is 0, §, -CH,-, -CH=CH-, or -C=C-, : w is CO, COO, CONR', CSO, CSNR', SO;, or SO,NR', . mandn independently from each other are 0 to 7 and m+n is 0 to 7, with the proviso thatmisnot0ifVisOorS,

Al is H, lower-alkyl, hydroxy-lower-alkyl, or lower-alkenyl,

A’and A* are hydrogen or lower-alkyl, or

Aland AZor A! and A’ are bonded to each other to form a ring and - Al- AZ or - A'- A’- are lower-alkylene or lower-alkenylene, optionally substituted by R?, in which one -CH,- group of -A'- A%- or -A'-A’- can optionally be replaced by NR’, S, or O, or

A? and A* are bonded to each other to form a ring together with the carbon atom to which they are attached and ASA is -(CHa);.5- which can optionally be mono- or multiply-substituted by lower-alkyl,

A’ is H, lower-alkyl, lower-alkenyl, or aryl-lower-alkyl,

AS is lower-alkyl, cycloalkyl, aryl, aryl-lower-alkyl, heteroaryl, heteroaryl-lower- alkyl, lower-alkoxy-carbonyl-lower-alkyl,

R? 1s hydroxy, hydroxy-lower-alkyl, lower-alkoxy, lower-alkoxycarbonyl,

N(R*R’), or thio-lower-alkoxy,

RY, R®, R* and R’ independently from each other are hydrogen or lower-alkyl, and pharmaceutically acceptable salts and/or pharmaceutically acceptable esters thereof. : Compounds of formula (I) as defined above, wherein A* and A* are not bonded to each other to form a ring together with the carbon atom to which they are attached, are preferred. In such compounds,

Al is H, lower-alkyl, hydroxy-lower-alkyl, or lower-alkenyl

A? is lower-alkyl, cycloalkyl, cycloalkyl-lower-alkyl, or lower-alkenyl, optionally substituted by R?, . A’and A* are hydrogen or lower-alkyl, or

Aland A? or A! and A’ are bonded to each other to form a ring and - Al- A%- or - Al A’- are lower-alkylene or lower-alkenylene, optionally substituted by R?, in which one -CH,- group of -A’- A%- or -A'-A’- can optionally be replaced by NR, S, or O.

Preferred are compounds of formula (I) and/or pharmaceutically acceptable salts thereof. Another preferred embodiment relates to compounds of formula (I) wherein U is alone pair and a further preferred embodiment relates to compounds of formula (I) wherein U is O.

A further preferred embodiment of the present invention relates to the trans-form of the compounds as defined above characterized by formula (Ia)

A°

AL pt yen

AN. > ~~ Va Si uN, (CH), (Chay (1a)

A wherein U,V, W, m, n, Al, AZ A%, A%, A’ and A® have the significances given above.

Compounds in which V represents O are particularly preferred, as are compounds wherein V is -CH,-. Compounds in which V represents -C=C- are also preferred. Further, compounds in which V represents -C=C- also relate to a preferred embodiment of the present invention.

Of the compounds of the present invention, those in which W represents CO, COO,

CONR!, CSNR, SO, or SO,NR’ and R’ is hydrogen are preferred, with those wherein W represents COO or SO; being particularly and individually preferred. Co

Compounds of the present invention in which n is 0 are preferred, as are those in which n is 1. Another preferred embodiment relates to compounds as defined above, wherein mis 1 to 6. In addition, compounds as defined above, wherein mis 0 and V is -C=C- or -C=C-, are also preferred.

In compounds wherein A' represents lower-alkyl, such a lower-alkyl group can optionally be substituted by fluorine. Other preferred compounds of the present invention are those in which A’ represents H, methyl, ethyl, isopropyl, 2-hydroxy-ethyl or 2- propenyl. Another group of preferred compounds of the present invention are those in which A? represents lower-alkyl, cycloalkyl-lower-alky, or lower-alkenyl, optionally . substituted with R?, wherein R* is hydroxy, methoxy, or ethoxycarbonyl, with those compounds wherein A” represents methyl, ethyl, 2-hydroxy-ethyl, 2-propenyl, propyl or v isopropyl being especially preferred.

Compounds of formula (I), wherein A! and A? are bonded to each other to form a ring and -A'-A’- is lower-alkylene or lower-alkenylene, optionally substituted by

R?, in which one -CH,- group of -A'-A%- can optionally be replaced by NR?, S, or O, wherein R” and R® are as defined above are also preferred, with compounds as defined above, wherein A' and A” are bonded to each other to form a ring and -A'-A%- is lower- alkylene or lower-alkenylene, optionally substituted by R? in which one -CH- group of -

A'-A%- can optionally be replaced by O, wherein R? is hydroxy or 2-hydroxyethyl being particularly preferred. In compounds wherein A' and A” are bonded to each other to form a ring, said ring is preferrably a 4-, 5-, or 6-membered ring such as e.g. piperidinyl or pyrrolidinyl. Preferred compounds as defined above are those wherein A' and A? are bonded to each other to form a ring and SAMA is -(CH;)s-. Such compounds consequently comprise a piperidinyl group.

A further preferred embodiment of the present invention relates to compounds of formula (I), wherein A? and/or A* represent hydrogen. Compounds of formula (I) as defined above, wherein A’ and A* are bonded to each other to form a cyclopropyl-ring together with the carbon atom to which they are attached and -A3-A% is -(CH,),- represent another preferred embodiment of the present invention. The term -(CH,);.5- denotes the groups -(CH;)2-, -(CHz)s-, -(CH,)s- and -(CHa)s-.

Compounds of formula (I), in which A’isH, lower-alkyl, lower-alkenyl, or benzyl optionally substituted with halogen are also preferred, with those wherein A’ represents methyl or ethyl being especially preferred.

Compounds of formula (I), wherein A® is lower-alkyl, cycloalkyl, phenyl, naphthyl, phenyl-lower-alkyl, pyridyl, indolyl, indolinyl, thienyl, thienyl-methylene, furyl- ‘ 30 methylene, benzodioxyl, chinolyl, isoxazolyl, or imidazolyl, optionally substituted by one or more substituents selected from the group consisting of lower-alkyl, lower-alkoxy, ) lower-alkylcarbonyl, lower-alkoxycarbonyl, fluorine, chlorine, bromine, CN, CFs, NO», or

N(R®R”), wherein R® and R’ independently from each other are hydrogen or lower-alkyl are another preferred embodiment of the present invention, with those compounds wherein A® is phenyl optionally substituted by one or more substituents selected from the group consisting of fluorine, chlorine, bromine and CFs, being more preferred, and with those compounds wherein A°® is 4-chloro-phenyl, 4-bromo-phenyl or 4-trifluoromethyl- phenyl being particularly preferred.

Preferred compounds of general formula (I) are those selected from the group . 5 consisting of trans-{4-[6-(Allyl-methyl-amino)-hexyloxy}-cyclohexyl}-methyl-carbamic acid 4-nitro- phenyl ester, trans-{4-[6-(Allyl-methyl-amino)-hexyloxy] -cyclohexyl}-methyl-carbamic acid naphthalen-2-yl ester, trans-{4-[6-(Allyl-methyl-amino)-hexyloxy]-cyclohexyl}-methyl-carbamic acid pentafluorophenylmethyl ester, trans-{4-{6-(Allyl-methyl-amino)-hexyloxy]-cyclohexyl}-methyl-carbamic acid benzyl ester, trans-{4-[6-(Allyl-methyl-amino)-hexyloxy] -cyclohexyl}-methyl-carbamic acid phenyl ester, ‘trans-{4-[6-(Allyl-methyl-amino)-hexyloxy]-cyclohexyl}-methyl-carbamic acid p-tolyl ester, trans-{4-[6-(Allyl-methyl-amino)-hexyloxy]-cyclohexyl}-methyl-carbamic acid 4-bromo- phenyl ester, trans-{4-[6-(Allyl-methyl-amino)-hexyloxy]-cyclohexyl}-methyl-carbamic acid 4-fluoro- phenyl ester, trans-{4-[6-(Allyl-methyl-amino)-hexyloxy]-cyclohexyl}-methyl-carbamic acid 4-chloro- phenyl ester, trans-{4-[6-(Allyl-methyl-amino)-hexyloxy]-cyclohexyl}-methyl-carbamic acid hexyl ester, trans-{4-[6-(Allyl-methyl-amino)-hexyloxy]-cyclohexyl}-methyl-carbamic acid 4- methoxy-phenyl ester, trans-{4-[6-(Allyl-methyl-amino)-hexyloxy]-cyclohexyl}-methyl-carbamic acid isobutyl ester, trans-{4-[6-(Allyl-methyl-amino)-hexyloxy]-cyclohexyl}-methyl-carbamic acid 4- trifluoromethyl-phenyl ester, : . trans- {4-[7-(Allyl-methyl-amino)-heptyloxy]-cyclohexyl}-methyl-carbamic acid 4-bromo- phenyl ester, } trans-{4- [5-(Allyl-methyl-amino)-pentyloxy]-cyclohexyl}-methyl-carbamic acid 4-bromo- phenyl ester, trans-{4-[4-(Allyl-methyl-amino)-butoxy]-cyclohexyl}-methyl-carbamic acid 4-bromo- phenyl ester, trans-{4-[7-(Allyl-methyl-amino)-heptyloxy]-cyclohexyl}-methyl-carbamic acid 4-fluoro-

phenyl ester, trans-{4-[5-(Allyl-methyl-amino)-pentyloxy]-cyclohexyl} -methyl-carbamic acid 4-fluoro- phenyl ester, - trans-{4-[5-(Allyl-methyl-amino)-pentyloxy]-cyclohexyl}-methyl-carbamic acid 4- trifluoromethyl-phenyl ester,

: trans-{4-[{4-(Allyl-methyl-amino)-butoxy]-cyclohexyl}-methyl-carbamic acid 4- trifluoromethyl-phenyl ester, {4-trans-[4-(Allyl-methyl-amino)-butoxy]-cyclohexyl}-methyl-carbamic acid 4-chloro- phenyl ester,

{4-trans-[4-(Allyl-methyl-amino)-butoxy]-cyclohexyl}-methyl-carbamic acid isobutyl ester,

{4-trans-[4-(Allyl-methyl-amino)-butoxy]-cyclohexyl}-methyl-carbamic acid phenyl ester, 4-({4-trans-[4-(Allyl-methyl-amino)-butoxy] -cyclohexyl} -methyl-carbamoyloxy)-benzoic acid methyl ester,

{4-trans-[4-(Allyl-methyl-amino)-butoxy]-cyclohexyl}-methyl-carbamic acid 4-methoxy- phenyl ester,

{4-trans-[4-(Allyl-methyl-amino)-butoxy]-cyclohexyl}-methyl-carbamic acid p-tolyl ester, trans-(4-{4-[Ethyl-(2-hydroxy-ethyl)-amino]-butoxy}-cyclohexyl)-methyl-carbamic acid 4-trifluoromethyl-phenyl ester,

trans-{4-(4-Diethylamino-butoxy)-cyclohexyl]-methyl-carbamic acid 4-trifluoromethyl- phenyl ester, trans- [4-(4-Dimethylamino-butoxy)-cyclohexyl]-methyl-carbamic acid 4-triflnoromethyl- phenyl ester, trans-(4-{4-[Bis-(2-hydroxy-ethyl)-amino]-butoxy}-cyclohexyl)-methyl-carbamic acid 4-

trifluoromethyl-phenyl ester, {4-trans-[3-(Allyl-methyl-amino)-propoxy]-cyclohexyl}-methyl-carbamic acid 4-fluoro- phenyl ester,

{4-trans-[3-(Allyl-methyl-amino)-propoxy] -cyclohexyl}-methyl-carbamic acid 4-bromo- phenyl ester,

trans{4-[6-(Allyl-methyl-amino)-hexyloxy]-cyclohexyl}-methyl-carbamic acid 2,4- difluoro-phenyl ester, [4-[Trans-4-(Allyl-methyl-amino)-butoxy]-cyclohexyl}-methyl-carbamic acid 3,4- : difluoro-phenyl ester,

[trans-4-(4-Dimethylamino-butoxy)-cyclohexyl]-methyl-carbamic acid 3,4-difluoro-

: 35 phenyl ester, (trans-4-{4-[Ethyl-(2-hydroxy-ethyl)-amino]-butoxy}-cyclohexyl)-methyl-carbamic acid 3,4-difluoro-phenyl ester, [trans-4-(4-Diethylamino-butoxy)-cyclohexyl]-methyl-carbamic acid 3,4-difluoro-phenyl ester,

ethyl-|trans-4-(4-piperidin-1-yl-butoxy)-cyclohexyl] -carbamic acid 3,4-difluoro-phenyl ester, [trans-4-(4-Azetidin-1-yl-butoxy)-cyclohexyl]-methyl-carbamic acid 3,4-difluoro-phenyl . ester,

Methyl-[trans-4-(4-morpholin-4-yl-butoxy)-cyclohexyl] -carbamic acid 3,4-difluoro- . phenyl ester,

Methyl-[trans-4-(4-pyrrolidin- 1-yl-butoxy)-cyclohexyl]-carbamic acid 3,4-difluoro- phenyl ester, (4-{trans-4-[Ethyl-(2-methoxy-ethyl)-amino]-butoxy}-cyclohexyl)-methyl-carbamic acid 3,4-difluoro-phenyl ester, trans-5-Chloro-thiophene-2-sulfonic acid {4-[6-(allyl-methyl-amino)-hexyloxy]- cyclohexyl}-methyl-amide, trans-N-{4-[6-(Allyl-methyl-amino)-hexyloxy]-cyclohexyl}-4,N-dimethyl- benzenesulfonamide, trans-Naphthalene-2-sulfonic acid {4-[6-(allyl-methyl-amino)-hexyloxy]-cyclohexyl}- methyl-amide, trans-N-{4-{6-(Allyl-methyl-amino)-hexyloxyl-cyclohexyl}-N-methyl- methanesulfonamide, trans-Quinoline-8-sulfonic acid {4-[6-(allyl-methyl-amino)-hexyloxy]-cyclohexyl}- methyl-amide, trans-N-{4-[6-(Allyl-methyl-amino)-hexyloxy]-cyclohexyl}-N-methyl-C-phenyl- methanesulfonamide, trans-3,5-Dimethyl-isoxazole-4-sulfonic acid {4-[6-(allyl-methyl-amino)-hexyloxy]- cyclohexyl}-methyl-amide, trans-Naphthalene-1-sulfonic acid {4-[6-(allyl-methyl-amino)-hexyloxy]-cyclohexyl}- methyl-amide, trans-N-{4-[6-(Allyl-methyl-amino)-hexyloxy]-cyclohexyl}-4-methoxy-N-methyl- benzenesulfonamide, trans-N-{4-[6-(Allyl-methyl-amino)-hexyloxy]-cyclohexyl}-N-methyl- benzenesulfonamide, trans-N-{4-[6-(Allyl-methyl-amino)-hexyloxy]-cyclohexyl}-4-fluoro-N-methyl- benzenesulfonamide, oo : trans-Thiophene-2-sulfonic acid {4-[6-(allyl-methyl-amino)-hexyloxy]-cyclohexyl}- methyl-amide, . 35 trans-N-{4-[6-(Allyl-methyl-amino)-hexyloxy]-cyclohexyl}-2-fluoro-N-methyl- benzenesulfonamide, trans-1-Methyl-1H-imidazole-4-sulfonic acid {4-[6-(allyl-methyl-amino)-hexyloxy]- cyclohexyl}-methyl-amide, trans-N-{4-[6-(Allyl-methyl-amino)-hexyloxy]-cyclohexyl}-4-tert-butyl-N-methyl-

benzenesulfonamide, trans-N-{4-[6-(Allyl-methyl-amino)-hexyloxy]-cyclohexyl}-4-butoxy-N-methyl- benzenesulfonamide, : trans-N-{4-[6-(Allyl-methyl-amino)-hexyloxy]-cyclohexyl}-4-chloro-N-methyl- benzenesulfonamide,

’ trans-N-{4-[6-(Allyl-methyl-amino)-hexyloxy]-cyclohexyl}-N-methyl-4-trifluoromethyl- benzenesulfonamide, trans-N-{4-[6-(Allyl-methyl-amino)-hexyloxy]-cyclohexyl}-4-bromo-N-methyl- benzenesulfonamide,

© 10 trans-N-{4-[6-(Allyl-methyl-amino)-hexyloxy]-cyclohexyl}-N-methyl-4-nitro- benzenesulfonamide, trans-4-Bromo-N-(4-{6-[(2-methoxy-ethyl)-methyl-amino]-hexyloxy}-cyclohexyl)-N- methyl-benzenesulfonamide, trans-N-(4-{6-[ (2-Methoxy-ethyl)-methyl-amino]-hexyloxy}-cyclohexyl)-N-methyl-4-

trifluoromethyl-benzenesulfonamide, trans-4-Bromo-N-methyl-N-[4-(6-morpholin-4-yl-hexyloxy)-cyclohexyl]- benzenesulfonamide, trans-N-[4-(6-Azetidin-1-yl-hexyloxy)-cyclohexyl]-4-bromo-N-methyl- benzenesulfonamide,

trans-4-Bromo-N-{4-[6-(butyl-methyl-amino)-hexyloxy]-cyclohexyl}-N-methyl- benzenesulfonamide, trans-4-Bromo-N-methyl-N-[4-(6-piperidin-1-yl-hexyloxy)-cyclohexyl}- benzenesulfonamide, trans-4-Bromo-N-{4-[6-(3,6-dihydro-2H-pyridin-1-yl)-hexyloxy]-cyclohexyl}-N-methyl-

benzenesulfonamide, trans-4-Bromo-N-(4-{6-[ethyl-(2-hydroxy-ethyl)-amino]-hexyloxy}-cyclohexyl)-N- methyl-benzenesulfonamide, trans-4-Bromo-N-{4-[6-(3-hydroxy-pyrrolidin-1-yl)-hexyloxy]-cyclohexyl}-N-methyl- benzenesulfonamide,

trans-4-Bromo-N-methyl-N-{4-[6-(methyl-propyl-amino)-hexyloxy]-cyclohexyl}- benzenesulfonamide, trans-4-Bromo-N-[4-(6-diallylamino-hexyloxy)-cyclohexyl]-N-methyl- o

: benzenesulfonamide, trans-4-Bromo-N-{4-[6-(4-hydroxymethyl-piperidin-1-yl)-hexyloxy]-cyclohexyl}-N-

: 35 methyl-benzenesulfonamide, trans-4-Bromo-N-(4-{6-[(2-hydroxy-ethyl)-methyl-amino]-hexyloxy}-cyclohexyl)-N- methyl-benzenesulfonamide, trans-4-Bromo-N-methyl-N-{4-[6-(4-methyl-piperidin-1-yl)-hexyloxy]-cyclohexyl}- benzenesulfonamide,

trans-4-Bromo-N-{4-[6-(4-hydroxy-piperidin-1-yl)-hexyloxy] -cyclohexyl}-N-methyl-

benzenesulfonamide,

trans-4-Bromo-N-{4-[6-(cyclopropylmethyl-methyl-amino)-hexyloxy]-cyclohexyl}-N- : methyl-benzenesulfonamide,

trans-[(6-{4-](4-Bromo-benzenesulfonyl)-methyl-amino]-cyclohexyloxy}-hexyl)-methyl-

’ amino] -acetic acid ethyl ester,

trans-N-[4-(6-Allylamino-hexyloxy)-cyclohexyl]-4-bromo-N-methyl-

benzenesulfonamide,

trans-4-Bromo-N-{4-[6-(2-hydroxy-ethylamino)-hexyloxy]-cyclohexyl}-N-methyl-

benzenesulfonamide, trans-4-Bromo-N-{4-(6-ethylamino-hexyloxy)-cyclohexyl]-N-methyl- benzenesulfonamide, trans-N-Methyl-N-{4-(6-morpholin-4-yl-hexyloxy)-cyclohexyl]-4-trifluoromethyl- benzenesulfonamide,

trans-N-[4-(6-Azetidin-1-yl-hexyloxy)-cyclohexyl]-N-methyl-4-trifluoromethyl- benzenesulfonamide, trans-N-{4-[6-(Butyl-methyl-amino)-hexyloxy]-cyclohexyl}-N-methyl-4-trifluoromethyl- - benzenesulfonamide, trans-N-Methyl-N-[4-(6-piperidin- 1-yl-hexyloxy)-cyclohexyl] -4-trifluoromethyl-

benzenesulfonamide, trans-N-{4-[{6-(3,6-Dihydro-2H-pyridin-1-yl1)-hexyloxy]-cyclohexyl}-N-methyl-4- trifluoromethyl-benzenesulfonamide, trans-N-(4-{6-[ Ethyl-(2-hydroxy-ethyl)-amino]-hexyloxy}-cyclohexyl)-N-methyl-4- trifluoromethyl-benzenesulfonamide,

trans-N-{4-[6-(3-Hydroxy-pyrrolidin-1-yl)-hexyloxy]-cyclohexyl}-N-methyl-4- trifluoromethyl-benzenesulfonamide, trans-N-Methyl-N-{4-[6-(methyl-propyl-amino)-hexyloxy]-cyclohexyl}-4- trifluoromethyl-benzenesulfonamide, trans-N-[4-(6-Diallylamino-hexyloxy)-cyclohexyl]-N-methyl-4-trifluoromethyl-

benzenesulfonamide, trans-N-{4-[6-(4-Hydroxymethyl-piperidin- 1-yl)-hexyloxy]-cyclohexyl}-N-methyl-4- trifluoromethyl-benzenesulfonamide, :

’ trans-N-(4-{6-[(2-Hydroxy-ethyl)-methyl-amino] -hexyloxy}-cyclohexyl)-N-methyl-4- trifluoromethyl-benzenesulfonamide,

: 35 trans-N-{4-[6-(4-Hydroxy-piperidin-1-yi)-hexyloxy]-cyclohexyl}-N-methyi-4- trifluoromethyl-benzenesulfonamide, trans-N-{4-{6-(Cyclopropylmethyl-methyl-amino)-hexyloxy]-cyclohexyl}-N-methyl-4- trifiuoromethyl-benzenesulfonamide, trans-[Methyl- (6-{4-[methyl-(4-trifluoromethyl-benzenesulfonyl)-amino} -

cyclohexyloxy}-hexyl)-amino]-acetic acid ethyl ester, trans-[ Methyl-(6-{4- [methyl-(4-trifluoromethyl-benzenesulfonyl)-amino]- cyclohexyloxy}-hexyl)-amino]-acetic acid, ’ trans-N-[4-(6-Allylamino-hexyloxy)- cyclohexyl] -N-methyl-4-trifluoromethyl- benzenesulfonamide, ’ N-{4-trans-[6-(Allyl-methyl-amino)-hexyloxy]-cyclohexyl}-3-chloro-N-methyl- benzenesulfonamide,

N-{4-trans-[6-(Allyl-methyl-amino)-hexyloxy]-cyclohexyl}-2,4-difluoro-N-methyl- benzenesulfonamide,

N-{4-trans-[6-(Allyl-methyl-amino)-hexyloxy]-cyclohexyl}-2-bromo-N-methyl- benzenesulfonamide,

N-{4-trans-[6-(Allyl-methyl-amino)-hexyloxy]-cyclohexyl}-3-bromo-N-methyl- benzenesulfonamide,

N-{4-trans-[6-(Allyl-methyl-amino)-hexyloxy]-cyclohexyl}-2,4-dichloro-N-methyl- benzenesulfonamide,

N-{4-trans-[6- (Allyl-methyl-amino)-hexyloxy]-cyclohexyl}-3-fluoro-N-methyl- benzenesulfonamide,

N-{4-trans-[6-(Allyl-methyl-amino)-hexyloxy]-cyclohexyl}-3,4-dichloro-N-methyl- benzenesulfonamide,

N-{4-trans-[6-(Allyl-methyl-amino)-hexyloxy]-cyclohexyl}-2-chloro-N-methyl- benzenesulfonamide,

N-{4-trans-{6-(Allyl-methyl-amino)-hexyloxy]-cyclohexyl}-3,4-difluoro-N-methyl- benzenesulfonamide, trans-N-[4-(3-Allylamino-propoxy)-cyclohexyl] -N-methyl-4-trifluoromethyl- benzenesulfonamide, trans-N-{4-[3-(Allyl-methyl-amino)-propoxy]-cyclohexyl}N-methyl4-trifluoromethyl- benzenesulfonamide, trans-N-(4-{3-[Ethyl-(2-hydroxy-ethyl)-amino]-propoxy}-cyclohexyl) N-methyl-4- trifluoromethyl-benzenesulfonamide, trans-N-[4-(3-Diethylamino-propoxy)-cyclohexyl]-N-methyl-4-trifluoromethyl- benzenesulfonamide, trans-N-(4-{3-[(2-Hydroxy-ethyl)-methyl-amino]-propoxy} -cyclohexyl)-N-methyl-4- ’ trifluoromethyl-benzenesulfonamide, trans-N-(4-{3-[Bis-(2-hydroxy-ethyl)-amino]-propoxy}-cyclohexyl) N-methyl-4- . 35 trifluoromethyl-benzenesulfonamide, trans-N-{4-[3-(Cyclopropylmethyl-methyl-amino)-propoxy]-cyclohexyl}-N-methyl-4- trifluoromethyl-benzenesulfonamide, trans-N-Methyl-N-{4-(3-pyrrolidin-1-yl-propoxy)- cyclohexyl] -4-trifluoromethyl- benzenesulfonamide,

trans-N-[4-(3-Ethylamino-propoxy)-cyclohexyl]-N-methyl-4-trifluoromethyl- benzenesulfonamide, trans-N-Methyl-N-[4-(3-morpholin-4-yl-propoxy)-cyclohexyl]- 4-trifluoromethyl- benzenesulfonamide, trans-N-{4-[3-(2-Hydroxy-ethylamino)-propoxy]-cyclohexyl}-N-methyl-4- . trifluoromethyl-benzenesulfonamide, trans-N-(4-{3-[Ethyl-(2-methoxy-ethyl)-amino] -propoxy}-cyclohexyl)-N-methyl-4- trifluoromethyl-benzenesulfonamide, trans-N-{4-[3-(3,6-Dihydro-2H-pyridin-1-yl)-propoxy]- cyclohexyl}-N-methyl-4- trifluoromethyl-benzenesulfonamide, trans-N-Methyl-N-{4-[3-(methyl-propyl-amino)-propoxy]- cyclohexyl}-4- trifluoromethyl-benzenesulfonamide, trans-N-{4-(4-Allylamino-butoxy)-cyclohexyl] -N-methyl-4-trifluoromethyl- benzenesulfonamide,

N-{4-trans-[4-(Allyl-methyl-amino)-butoxy]-cyclohexyl}-N-methyl-4-trifluoromethyl- benzenesulfonamide, trans-N-(4-{4-[Ethyl-(2-hydroxy-ethyl)-amino]-butoxy}-cyclohexyl)-N-methyl-4- trifluoromethyl-benzenesulfonamide, trans-N-[4-(4-Diethylamino-butoxy)-cyclohexyl] -N-methyl-4-triftuoromethyl- benzenesulfonamide, trans-N-[4-(4-Dimethylamino-butoxy)-cyclohexyl]-N-methyl-4-trifluoromethyl- benzenesulfonamide, trans-N-(4-{4-[(2-Methoxy-ethyl)-methyl-amino]-butoxy}-cyclohexyl)-N-methyl-4- trifluoromethyl-benzenesulfonamide, trans-N-(4-{4-[(2-Hydroxy-ethyl)-methyl-amino]-butoxy}-cyclohexyl)-N-methyl-4- trifluoromethyl-benzenesulfonamide, trans-N-(4-{4-[Bis-(2-hydroxy-ethyl)-amino]-butoxy}-cyclohexyl)-N-methyl-4- trifluoromethyl-benzenesulfonamide, trans-N-{4-[4-(Cyclopropylmethyl-methyl-amino)-butoxy]- cyclohexyl}-N-methyl-4- trifluoromethyl-benzenesulfonamide, trans-N-[4-(4-Ethylamino-butoxy)-cyclohexyl]-N-methyl-4-trifluoromethyl- benzenesulfonamide, : trans-N-Methyl-N-[4-(4-morpholin-4-yl-butoxy)-cyclohexyl]-4-trifluoromethyl- benzenesulfonamide, . 35 trans-N-{4-[4-(2-Hydroxy-ethylamino)-butoxy}-cyclohexyl}-N-methyl-4- trifluoromethyl-benzenesulfonamide, trans-N-{4-[4-(3,6-Dihydro-2H-pyridin-1-yl)-butoxy]- cyclohexyl}-N-methyl-4- trifluoromethyl-benzenesulfonamide, trans-N-Methyl-N-{4-[4-(methyl-propyl-amino)-butoxy]- cyclohexyl}-4-trifluoromethyl-

benzenesulfonamide, trans-N-(4-{4-[Ethyl-(2-methoxy-ethyl)-amino]-butoxy}-cyclohexyl)-N-methyl-4- trifluoromethyl-benzenesulfonamide, . trans-N-(4-{3-](2-Methoxy-ethyl)-methyl-amino]-propoxy}-cyclohexyl)-N-methyl-4- trifluoromethyl-benzenesulfonamide, ‘ N-{4-trans-[3-( Allyl-methyl-amino)-propoxy] -cyclohexyl}-4-chloro-N-methyl- benzenesulfonamide,

N-{4-trans-[4-(Allyl-methyl-amino)-butoxy]-cyclohexyl}-4-chloro-N-methyl- benzenesulfonamide,

N-{4-trans-{4-(Allyl-methyl-amino)-butoxy]-cyclohexyl}-4-bromo-N-methyl- benzenesulfonamide,

N-{4-trans-[4-(Allyl-methyl-amino)-butoxy]-cyclohexyl}-N-methyl-C-phenyl- methanesulfonamide,

N-{4-trans-[4-(Allyl-methyl-amino)-butoxy] -cyclohexyl}-4-fluoro-N-methyl- benzenesulfonamide,

N-{4-trans-[4-(Allyl-methyl-amino)-butoxy]-cyclohexyl}-2-fluoro-N-methyl- benzenesulfonamide,

N-{4-trans-[4- (Allyl-methyl-amino)-butoxy]-cyclohexyl}-N-methyl-benzenesulfonamide, 5-Chloro-thiophene-2-sulfonic acid {4-trans-[4-(allyl-methyl-amino)-butoxy]- cyclohexyll-methyl-amide, trans-Pyridine-2-carboxylic acid {4-[6-(allyl-methyl-amino)-hexyloxy]-cyclohexyl}- methyl-amide, trans- 1H-Indole-2-carboxylic acid {4-[6-(allyl-methyl-amino)-hexyloxy]-cyclohexyl}- methyl-amide, trans-N-{4-[6-(Allyl-methyl-amino)-hexyloxy]-cyclohexyl}-N-methyl-benzamide, trans-N-{4-[6-(Allyl-methyl-amino)-hexyloxy]-cyclohexyl}-4-chloro-N-methyl- benzamide, trans-N-{4-[6-(Allyl-methyl-amino)-hexyloxy]-cyclohexyl}-4-fluoro-N-methyl- benzamide, trans-N-{4-[6-(Allyl-methyl-amino)-hexyloxy]-cyclohexyl}-4-bromo-N-methyl- benzamide, trans-N-{4-[6-(Allyl-methyl-amino)-hexyloxy]-cyclohexyl}-N-methyl-4-trifluoromethyl- - benzamide, trans-Thiophene-3-carboxylic acid {4-[6-(allyl-methyl-amino)-hexyloxy]-cyclohexyl}- . 35 methyl-amide, trans-5-Bromo-thiophene-2-carboxylic acid {4-[6-(allyl-methyl-amino)-hexyloxy]- cyclohexyl}-methyl-amide, trans-N-{4-({6-(Allyl-methyl-amino)-hexyloxy]-cyclohexyl}-N-methyl-2-thiophen-3-yi- acetamide,

trans-N-{4-[6-(Allyl-methyl-amino)-hexyloxy] -cyclohexyl}-2-(2,4-difluoro-phenyl)-N- methyl-acetamide, trans-5-Fluoro-1H-indole-2-carboxylic acid {4-[6-(allyl-methyl-amino)-hexyloxy]- ' cyclohexyl}-methyl-amide, trans-N-{4-[6-(Allyl-methyl-amino)-hexyloxy]-cyclohexyl}-2-(4-fluoro-phenyl)-N- . methyl-acetamide, trans-1H-Indole-5-carboxylic acid {4-[6-(allyl-methyl-amino)-hexyloxy]-cyclohexyl}- methyl-amide, trans-N-{4-[6-(Allyl-methyl-amino)-hexyloxy] -cyclohexyl}-3-chloro-N-methyl-

benzamide, trans-N-{4-[6-(Allyl-methyl-amino)-hexyloxy]-cyclohexyl}-4-fluoro-3,N-dimethyl- benzamide, trans-N-{4-[6-(Allyl-methyl-amino)-hexyloxy]-cyclohexyl}-N-methyl-4-nitro-benzamide, trans-N-{4-[6-(Allyl-methyl-amino)-hexyloxy] -cyclohexyl}-4,N-dimethyl-benzamide,

trans-N-{4-[6-(Allyl-methyl-amino)-hexyloxy] -cyclohexyl}-3-cyano-N-methyl- benzamide, trans-N-{4-[6-(Allyl-methyl-amino)-hexyloxy]-cyclohexyl}-3,N-dimethyl-benzamide, trans-N-{4-[6-(Allyl-methyl-amino)-hexyloxy]-cyclohexyl}-3,4-dimethoxy-N-methyl- benzamide,

trans-N-{4-[6-(Allyl-methyl-amino)-hexyloxy]-cyclohexyl}-4-methoxy-N-methyl- benzamide, trans-N-{4-[6-(Allyl-methyl-amino)-hexyloxy]-cyclohexyl}-4-fluoro-N-methyl-3-nitro- benzamide, trans-4-Acetyl-N-{4-[6-(allyl-methyl-amino)-hexyloxy]-cyclohexyl}-N-methyl-

benzamide, trans-N-{4-({7-(Allyl-methyl-amino)-heptyloxy]-cyclohexyl}-N-methyl-4-trifluoromethyl- benzamide, trans-N-{4-[5-(Allyl-methyl-amino)-pentyloxy]-cyclohexyl}-N-methyl-4-trifluoromethyl- benzamide,

trans-N-{4-[4-(Allyl-methyl-amino)-butoxy]-cyclohexyl}-3-cyano-N-methyl-benzamide, trans-N-{4-[5-(Allyl-methyl-amino)-pentyloxy]-cyclohexyl}-4-bromo-N-methyl- benzamide, :

: trans-N-{4-[4-(Allyl-methyl-amino)-butoxy]-cyclohexyl}-4-bromo-N-methyl-benzamide, trans-5-Bromo-thiophene-2-carboxylic acid {4-[4-(allyl-methyl-amino)-butoxy]-

. 35 cyclohexyl}-methyl-amide, trans-N-{4-[5-(Allyl-methyl-amino)-pentyloxyl-cyclohexyl}-4-fluoro-N-methyl- benzamide, trans-N-{4-[4-(Allyl-methyl-amino)-butoxy]-cyclohexyl}-4-fluoro-N-methyl-benzamide, trans-1-{4-[6-(Allyl-methyl-amino)-hexyloxy]-cyclohexyl}-3-(2,4-difluoro-phenyl)-1-

methyl-urea, trans-1-{4-[6-(Allyl-methyl-amino)-hexyloxy] -cyclohexyl}-3-(2,4-dimethoxy-phenyl)-1- methyl-urea, : trans-1-{4-[6-(Allyl-methyl-amino)-hexyloxy] -cyclohexyl}-3-(4-fluoro-phenyl)-1-methyl- urea, ‘ trans-1-{4-[6-(Allyl-methyl-amino)-hexyloxy]-cyclohexyl}-3-(4-methoxy-phenyl)-1- methyl-urea, trans-1-{4-][6-(Allyl-methyl-amino)-hexyloxy] -cyclohexyl}-1-methyl-3-p-tolyl-urea, trans-1-{4-[6-(Allyl-methyl-amino)-hexyloxy]-cyclohexyl}-3- (4-methoxy-2-methyl-

phenyl)-1-methyl-urea, trans-1-{4-[6-(Allyl-methyl-amino)-hexyloxy]-cyclohexyl}-3-(2,4-dimethyl-phenyl)-1- methyl-urea, trans-1-{4-[6-(Allyl-methyl-amino)-hexyloxy]-cyclohexyl}-1-methyl-3-(3,4,5-trimethoxy- phenyl)-urea,

trans-1-{4-[6-(Allyl-methyl-amino)-hexyloxy]-cyclohexyl}-3-(3,4-dimethyl-phenyl)-1- methyl-urea, trans-3-(4-Acetyl-phenyl)-1-{4-[6- (allyl-methyl-amino)-hexyloxy]-cyclohexyl}-1-methyl- urea, trans-1-{4-[6-(Allyl-methyl-amino)-hexyloxy]-cyclohexyl}-3-(4-chloro-phenyl)-1-

methyl-urea, trans-1-{4-[6-(Allyl-methyl-amino)-hexyloxy]-cyclohexyl}-1-methyl-3-phenyl-urea, trans-1-{4-[6-(Allyl-methyl-amino)-hexyloxy]-cyclohexyl}-1-methyl-3-(4- trifluoromethyl-phenyl)-urea, trans-1-{4-[6-(Allyl-methyl-amino)-hexyloxy]-cyclohexyl}-3-(3,4-dichloro-phenyl)-1-

methyl-urea, trans-1-{4-[6-(Allyl-methyl-amino)-hexyloxy]-cyclohexyl}-3-(4-bromo-phenyl)-1- methyl-urea, trans-1-{4-[6-(Allyl-methyl-amino)-hexyloxy]-cyclohexyl}-1-methyl-3-naphthalen-2-yl- urea,

trans-1-{4-[6-(allyl-methyl-amino)-hexyloxy]-cyclohexyl}-1 -methyl-3- (4-nitro-phenyl)- urea, trans-1-{4-[6-(Allyl-methyl-amino)-hexyloxy] -cyclohexyl}-3- (4-dimethylamino-phenyl)-

: 1-methyl-urea, trans-1-{4-[7-(Allyl-methyl-amino)-heptyloxy]-cyclohexyl}-1-methyl-3-p-tolyl-urea,

trans-1-{4-[7-(Allyl-methyl-amino)-heptyloxy]-cyclohexyl}-3-(4-fluoro-phenyl)-1- methylurea, trans-1-{4-[7-(Allyl-methyl-amino)-heptyloxy]-cyclohexyl}-3-(4-bromo-phenyl)-1- methylurea, trans-1-{4-[7-(Allyl-methyl-amino)-heptyloxy]-cyclohexyl}-3-(4-butyl-phenyl)-1-

methylurea, trans-1-{4-[5-(Allyl-methyl-amino)-pentyloxy]-cyclohexyl}- 1-methyl-3-p-tolyl-urea, trans-1-{4-[5-(Allyl-methyl-amino)-pentyloxy]-cyclohexyl}-3-(4-fluoro-phenyl)-1- methylurea, trans-1-{4-[5-(Allyl-methyl-amino)-pentyloxy]-cyclohexyl}-3-(4-bromo-phenyl)-1- ’ methylurea, trans-1-{4-[4-(Allyl-methyl-amino)-butoxy] -cyclohexyl}-1-methyl-3-p-tolyl-urea, trans-1-{4-[4-(Allyl-methyl-amino)-butoxy]-cyclohexyl}-3-(4-fluoro-phenyl)-1-methyl- urea,

trans-1-{4-[4-(Allyl-methyl-amino)-butoxy]-cyclohexyl}-3-(4-bromo-phenyl)-1-methyl- urea, trans-1-{4-[4-(Allyl-methyl-amino)-butoxy]-cyclohexyl}-3-(4-butyl-phenyl)-1-methyl- urea, trans-Methyl-{4-[4-(methyl-propyl-amino)-butoxy}-cyclohexyl}-carbamic acid 4-

trifluoromethyl-phenyl ester, trans-N-(4-[6-(Allyl-methyl-amino)-hexyloxy]-cyclohexyl)-4-bromo-N-methyl- benzenesulfonamide, trans-4-Bromo-N-[4-(6-dimethylamino-hexyloxy)-cyclohexyl]-N-methyl- benzenesulfonamide,

trans-4-Bromo-N-(4-{6-[(2-methoxy-ethyl)-methyl-amino]-hexyloxy}-cyclohexyl)-N- methyl-benzenesulfonamide, trans-N-(4-[6-(Allyl-methyl-amino)-hexyloxy]-cyclohexyl)-N-methyl-4-trifluoromethyl- benzenesulfonamide, trans-N-[4-(6-Dimethylamino-hexyloxy)-cyclohexyl]-N-methyl-4-trifluoromethyl-

benzenesulfonamide, trans-N-(4-{6-[(2-Methoxy-ethyl)-methyl-amino]-hexyloxy}-cyclohexyl)-N-methyl-4- trifluoromethyl-benzenesulfonamide, trans-4-Bromo-N-[4-(6-diethylamino-hexyloxy)-cyclohexyl]-N-methyl- benzenesulfonamide,

trans-4-Bromo-N-{4-[6-(isopropyl-methyl-amino)-hexyloxy]-cyclohexyl}-N-methyl- benzenesulfonamide, trans-4-Bromo-N-methyl-N-[4-(6-pyrrolidin- 1-yl-hexyloxy)-cyclohexyl]-

’ benzenesulfonamide, trans-N-[4-(6-Diethylamino-hexyloxy)-cyclohexyl]-N-methyl-4-trifluoromethyl-

: 35 benzenesulfonamide, trans-N-{4-[6-(Isopropyl-methyl-amino)-hexyloxy]-cyclohexyl}-N-methyl-4- trifluoromethyl-benzenesulfonamide, trans-N-Methyl-N-[4-(6-pyrrolidin-1-yl-hexyloxy)-cyclohexyl]-4-trifluoromethyl- benzenesulfonamide,

trans-4-Chloro-N-(4-{6-[(2-methoxy-ethyl)-methyl-amino]-hexyloxy}-cyclohexyl)-N- methyl-benzenesulfonamide, trans-(4-{6-[(2-Methoxy-ethyl)-methyl-amino]-hexyloxy}-cyclohexyl)-methyl-carbamic : acid 4-chloro-phenyl ester, trans-4-Chloro-N-(4-{6-[(2-methoxy-ethyl)-methyl-amino]-hexyloxy}-cyclohexyl)-

: benzenesulfonamide, trans-4-Bromo-N-(4-{6-[(2-methoxy-ethyl)-methyl-amino]-hexyloxy}-cyclohexyl)- benzenesulfonamide, trans-4-Chloro-N-(4-{6-[ (2-methoxy-ethyl)-methyl-amino]-hexyloxy}-cyclohexyl)-N-

propyl-benzenesulfonamide, trans-4-Bromo-N-(4-{6-[(2-methoxy-ethyl)-methyl-amino]-hexyloxy}-cyclohexyl)-N- propyl-benzenesulfonamide, trans-4-Chloro-N-(4-{6-[(2-methoxy-ethyl)-methyl-amino]-hexyloxy}-cyclohexyl)-N- (2,4,5-trifluoro-benzyl)-benzenesulfonamide,

trans-4-Bromo-N-(4-{6-[(2-methoxy-ethyl)-methyl-amino]}-hexyloxy}-cyclohexyl)-N- (2,4,5-trifluoro-benzyl)-benzenesulfonamide, trans-(4-{6-[(2-Methoxy-ethyl)-methyl-amino]-hexyloxy}-cyclohexyl)-carbamic acid 4- - chloro-phenyl ester, trans-Ethyl-(4-{6-[(2-methoxy-ethyl)-methyl-amino]-hexyloxy}-cyclohexyl)-carbamic acid 4-chloro-phenyl ester, trans-(4-{6-[(2-Methoxy-ethyl)-methyl-amino]-hexyloxy}-cyclohexyl)-propyl-carbamic acid 4-chloro-phenyl ester, trans-(4-{6-[(2-Methoxy-ethyl)-methyl-amino]-hexyloxy}-cyclohexyl)-(2,4,5-trifluoro- benzyl)-carbamic acid 4-chloro-phenyl ester,

trans-Ethyl-(4-{6-[ethyl-(2-hydroxy-ethyl)-amino]-hexyloxy}-cyclohexyl)-carbamic acid benzyl ester, trans-Benzyl-(4-{6-[ethyl-(2-hydroxy-ethyl)-amino]-hexyloxy}-cyclohexyl)-carbamic acid benzyl ester, trans-(4-{6-[Ethyl-(2-hydroxy-ethyl)-amino]-hexyloxy}-cyclohexyl)-methyl-carbamic

530 acid benzyl ester, trans-Allyl-(4-{6- [ethyl-(2-hydroxy-ethyl)-amino]-hexyloxy}-cyclohexyl)-carbamic acid benzyl ester,

- trans-(4-{6-[Ethyl-(2-hydroxy-ethyl)-amino]-hexyloxy}-cyclohexyl)-(2,4,5-trifluoro- benzyl)-carbamic acid benzyl ester,

: 35 trans-[4-(6-Azetidin-1-yl-hexyloxy)-cyclohexyl]-ethyl-carbamic acid benzyl ester, trans-[4-(6-Azetidin-1-yl-hexyloxy)-cyclohexyl]-benzyl-carbamic acid benzyl ester, trans-[4-(6-Azetidin-1-yl-hexyloxy)-cyclohexyl] -methyl-carbamic acid benzyl ester, trans-Ethyl-(4-{6-[(2-hydroxy-ethyl)-methyl-amino]-hexyloxy}-cyclohexyl)-carbamic acid benzyl ester,

trans-Benzyl-(4-{6-[(2-hydroxy-ethyl)-methyl-amino]-hexyloxy}-cyclohexyl)-carbamic acid benzyl ester, trans-(4-{6-[(2-Hydroxy-ethyl)-methyl-amino]-hexyloxy}-cyclohexyl)-methyl-carbamic ‘ acid benzyl ester, trans-Allyl-(4-{6-[(2-hydroxy-ethyl)-methyl-amino]-hexyloxy}-cyclohexyl)-carbamic acid : benzyl ester, trans-(4-{6-[(2-Hydroxy-ethyl)-methyl-amino]-hexyloxy}-cyclohexyl)-(2,4,5-trifluoro- benzyl)-carbamic acid benzyl ester, trans-Ethyl-(4-{6-[(2-methoxy-ethyl)-methyl-amino]-hexyloxy}-cyclohexyl)-carbamic acid benzyl ester, trans-Benzyl-(4-{6-[(2-methoxy-ethyl)-methyl-amino]-hexyloxy}-cyclohexyl)-carbamic acid benzyl ester, trans-(4-{6-{(2-Methoxy-ethyl)-methyl-amino]-hexyloxy}-cyclohexyl)-methyl-carbamic acid benzyl ester,

trans-(4-{6-[(2-Methoxy-ethyl)-methyl-amino]-hexyloxy}-cyclohexyl)-(2,4,5-trifluoro- benzyl)-carbamic acid benzyl ester, trans-Ethyl-[4-(6-morpholin-4-yl-hexyloxy)-cyclohexyl] -carbamic acid benzyl ester, trans-Benzyl-[4-(6-morpholin-4-yl-hexyloxy)-cyclohexyl] -carbamic acid benzyl ester, trans-Methyl-[4-(6-morpholin-4-yl-hexyloxy)-cyclohexyl]-carbamic acid benzyl ester,

trans-Allyl-[4-(6-morpholin-4-yl-hexyloxy)-cyclohexyl] -carbamic acid benzyl ester, trans-[4-(6-Morpholin-4-yl-hexyloxy)-cyclohexyl]-(2,4,5-trifluoro-benzyl)-carbamic acid benzyl ester, trans-Ethyl-[4-(6-pyrrolidin- 1-yl-hexyloxy)-cyclohexyl]-carbamic acid benzyl ester, trans-Benzyl-[4-(6-pyrrolidin-1-yl-hexyloxy)-cyclohexyl]-carbamic acid benzyl ester,

trans-Methyl-[4-(6-pyrrolidin-1-yl-hexyloxy)-cyclohexyl]-carbamic acid benzyl ester, trans-Allyl-[4-(6-pyrrolidin-1-yl-hexyloxy)-cyclohexyl]-carbamic acid benzyl ester, trans-[4-(6-Pyrrolidin- 1-yl-hexyloxy)-cyclohexyl]-(2,4,5-trifluoro-benzyl)-carbamic acid benzyl ester, trans-{4-[6-(Allyl-methyl-amino)-hexyloxy]-cyclohexyl}-methyl-carbamic acid benzyl ester, trans-{4-[6-(Allyl-methyl-amino)-hexyloxy]-cyclohexyl}-ethyl-carbamic acid benzyl ester, trans-Allyl-{4-[6-(allyl-methyl-amino)-hexyloxy] -cyclohexyl}-carbamic acid benzyl ester,

- trans-{4-[6-(Allyl-methyl-amino)-hexyloxy] -cyclohexyl}-benzyl-carbamic acid benzyl ester,

trans-{4-[6-(Allyl-methyl-amino)-hexyloxy]-cyclohexyl}-(2,4,5-trifluoro-benzyl)- carbamic acid benzyl ester, trans-[4-(6-Dimethylamino-hexyloxy)-cyclohexyl]-methyl-carbamic acid benzyl ester, trans- [4-(6-Dimethylamino-hexyloxy)-cyclohexyl]-ethyl-carbamic acid benzyl ester, trans-Allyl-[4- (6-dimethylamino-hexyloxy)-cyclohexyl]-carbamic acid benzyl ester,

trans-Benzyl-[4-(6-dimethylamino-hexyloxy)-cyclohexyl]-carbamic acid benzyl ester, trans-[4-(6-Dimethylamino-hexyloxy)-cyclohexyl]-(2,4,5-trifluoro-benzyl)-carbamic acid benzyl ester, : trans-(4-[5-(Allyl-methyl-amino)-pentyloxy]-cyclohexyl)-methyl-carbamic acid tert-butyl ester, ‘ trans-(4-[3-(Allyl-methyl-amino)-propoxy]-cyclohexyl)-methyl-carbamic acid tert-butyl ester, trans-(4-[4-(Allyl-methyl-amino)-butoxy]-cyclohexyl)-methyl-carbamic acid tert-butyl ester,

trans-(4-[7-(Allyl-methyl-amino)-heptyloxy]-cyclohexyl)-methyl-carbamic acid tert-butyl ester, trans-4-Chloro-N-ethyl-N-(4-{6-[ (2-methoxy-ethyl)-methyl-amino]-hexyloxy}- cyclohexyl)-benzenesulfonamide, trans-4-Bromo-N-ethyl-N-(4-{6-[(2-methoxy-ethyl)-methyl-amino]-hexyloxy}-

cyclohexyl)-benzenesulfonamide, trans-{4-[4-(Allyl-methyl-amino)-butoxy]-cyclohexyl}-methyl-carbamic acid 4-chloro- phenyl ester, trans-{4-[5-(Allyl-methyl-amino)-pentyloxy]-cyclohexyl}-methyl-carbamic acid 4-chloro- phenyl ester,

trans-(4-{6-[Ethyl-(2-hydroxy-ethyl)-amino]-hexyloxy}-cyclohexyl)-methyl-carbamic acid 4-chloro-phenyl ester, trans-(4-{4-[Ethyl-(2-hydroxy-ethyl)-amino]-butoxy}-cyclohexyl)-methyl-carbamic acid 4-chloro-phenyl ester, trans-(4-{5-[Ethyl-(2-hydroxy-ethyl)-amino]-pentyloxy}-cyclohexyl)-methyl-carbamic acid 4-chloro-phenyl ester, trans-[4-(6-Dimethylamino-hexyloxy)-cyclohexyl]-methyl-carbamic acid 4-chloro-phenyl ester, trans-[4-(4-Dimethylamino-butoxy)-cyclohexyl]-methyl-carbamic acid 4-chloro-phenyl ester,

trans-[4-(5-Dimethylamino-pentyloxy)-cyclohexyl]-methyl-carbamic acid 4-chloro- phenyl ester, trans-(4-{6-[Ethyl-(2-methoxy-ethyl)-amino]-hexyloxy}-cyclohexyl)-methyl-carbamic

’ acid 4-chloro-phenyl ester, trans-(4-{4-[Ethyl-(2-methoxy-ethyl)-amino]-butoxy}-cyclohexyl)-methyl-carbamic acid

: 35 4-chloro-phenyl ester, trans-{4-[3-(Allyl-methyl-amino)-propoxy]-cyclohexyl}-methyl-carbamic acid 4-chloro- phenyl ester, trans-(4-{3-[Ethyl-(2-methoxy-ethyl)-amino]-propoxy}-cyclohexyl)-methyl-carbamic acid 4-chloro-phenyl ester,

trans-(4-{5-[Ethyl-(2-methoxy-ethyl)-amino]-pentyloxy}-cyclohexyl)-methyl-carbamic acid 4-chloro-phenyl ester, trans-[4-(3-Dimethylamino-propoxy)- cyclohexyl] -methyl-carbamic acid 4-chloro-phenyl ’ ester, trans-(4-{3-[Ethyl-(2-hydroxy-ethyl)-amino]-propoxy}-cyclohexyl)-methyl-carbamic acid ’ 4-chloro-phenyl ester, trans-Methyl-[4-(3-piperidin-1-yl-propoxy)-cyclohexyl] -carbamic acid 4-chloro-phenyl ester, trans-Methyl-[4-(4-piperidin-1-yl-butoxy)-cyclohexyl]-carbamic acid 4-chloro-phenyl ester, trans-Methyl-[4-(6-piperidin-1-yl-hexyloxy)-cyclohexyl] -carbamic acid 4-chloro-phenyl ester, trans-Methyl-[4-(5-piperidin- 1-yl-pentyloxy)-cyclohexyl]-carbamic acid 4-chloro-phenyl ester,

trans-{4-(3-Diethylamino-propoxy)-cyclohexyl]-methyl-carbamic acid 4-chloro-phenyl ester, trans-{4-(6-Diethylamino-hexyloxy)-cyclohexyl]-methyl-carbamic acid 4-chloro-phenyl ester, trans-[4-(4-Diethylamino-butoxy)-cyclohexyl]-methyl-carbamic acid 4-chloro-phenyl ester, trans-[4-(5-Diethylamino-pentyloxy)-cyclohexyl]-methyl-carbamic acid 4-chloro-phenyl ester, trans-Methyl-[4-(3-pyrrolidin-1-yl-propoxy)-cyclohexyl]-carbamic acid 4-chloro-phenyl ester,

trans-Methyl-(4-(6-pyrrolidin-1-yl-hexyloxy)-cyclohexyl]-carbamic acid 4-chloro-phenyl ester, trans-(4-{6-[(2-Hydroxy-ethyl)-methyl-amino]-hexyloxy}-cyclohexyl)-methyl-carbamic acid 4-chloro-phenyl ester, trans-(4-{4-[(2-Hydroxy-ethyl)-methyl-amino] -butoxy}- cyclohexyl)-methyl-carbamic acid 4-chloro-phenyl ester, trans-(4-{5-[(2-Hydroxy-ethyl)-methyl-amino] -pentyloxy}-cyclohexyl)-methyl-carbamic acid 4-chloro-phenyl ester,

‘ trans-Methyl- [4-(4-pyrrolidin-1-yl-butoxy)-cyclohexyl] - carbamic acid 4-chloro-phenyl ester,

: 35 trans-Methyl-[4-(5-pyrrolidin-1-yl-pentyloxy)-cyclohexyl]-carbamic acid 4-chloro-phenyl ester, trans-(4-{3-[(2-Hydroxy-ethyl)-methyl-amino]-propoxy}-cyclohexyl)-methyl-carbamic acid 4-chloro-phenyl ester, trans-[4-(5-Dimethylamino-pentyloxy)-cyclohexyl]-methyl-carbamic acid 4-chloro-

phenyl ester N-oxide, trans-{4-[5-(Allyl-methyl-amino)-pentyl]-cyclohexyl}-methyl-carbamic acid 4- trifluoromethyl-phenyl ester, ’ trans-(4-{5-] Ethyl-(2-hydroxy-ethyl)-amino] -pentyl}-cyclohexyl)-methyl-carbamic acid 4-trifluoromethyl-phenyl ester, : trans-{4-[5-(Allyl-methyl-amino)-pentyl]-cyclohexyl}-methyl-carbamic acid 4-bromo- phenyl ester, trans-(4-{5- [Ethyl-(2-hydroxy-ethyl)-amino]-pentyl}-cyclohexyl)-methyl-carbamic acid 4-bromo-phenyl ester,

trans-{4-[5-(Allyl-methyl-amino)-pentyl]-cyclohexyl}-methyl-carbamic acid 3,4-difluoro- phenyl ester, trans-(4-{5-[Ethyl-(2-hydroxy-ethyl)-amino]-pentyl}-cyclohexyl)-methyl-carbamic acid 3,4-difluoro-phenyl ester, trans-{4-[5-(Allyl-methyl-amino)-pentyl]-cyclohexyl}-methyl-carbamic acid 4-chloro-

phenyl ester, trans-{4-[3-(Allyl-methyl-amino)-propoxymethyl] -cyclohexyl}-methyl-carbamic acid 4- chloro-phenyl ester, trans-(4-{3-[Ethyl-(2-hydroxy-ethyl)-amino]-propoxymethyl}-cyclohexyl)-methyl- carbamic acid 4-chloro-phenyl ester,

trans-[4-(3-Azetidin-1-yl-propoxymethyl)-cyclohexyl]-methyl-carbamic acid 4-chloro- phenyl ester, trans-Methyl-[4-(3-piperidin-1-yl-propoxymethyl)-cyclohexyl] -carbamic acid 4-chloro- phenyl ester, trans-(4-{3-[Ethyl-(2-methoxy-ethyl)-amino]-propoxymethyl}-cyclohexyl)-methyl-

carbamic acid 4-chloro-phenyl ester, trans-{4-[4-(Allyl-methyl-amino)-butoxymethyl]-cyclohexyl}-methyl-carbamic acid 4- chloro-phenyl ester, trans-{4-[2-(Allyl-methyl-amino)-ethoxymethyl}-cyclohexyl}-methyl-carbamic acid 4- chloro-phenyl ester,

trans-N-{4-[3-(Allyl-methyl-amino)-propoxymethyl]-cyclohexyl}-N-methyl-4- triftuoromethyl-benzenesulfonamide, (trans)-N-(4-{3-[Ethyl- (2-hydroxy-ethyl)-amino]-propoxymethyl}-cyclohexyl)-N-

’ methyl-4-trifluoromethyl-benzenesulfonamide, trans-N-[4-(3-Azetidin-1-yl-propoxymethyl)-cyclohexyl]-N-methyl-4-trifluoromethyl-

: 35 benzenesulfonamide, trans-N-Methyl-N-[4-(3-piperidin-1-yl-propoxymethyl)-cyclohexyl]-4-trifluoromethyl- benzenesulfonamide, (trans)-N-[4-(2-Dimethylamino-ethylsulfanylmethyl)-cyclohexyl]-N-methyl-4- trifluoromethyl-benzenesulfonamide,

trans-N-[4-(2-Diethylamino-ethylsulfanylmethyl)-cyclohexyl] -N-methyl-4- trifluoromethyl-benzenesulfonamide, trans-N-{4-[2-(Allyl-methyl-amino)-ethylsulfanylmethyl]-cyclohexyl}-N-methyl-4~ ‘ trifluoromethyl-benzenesulfonamide, trans-[4-(2-Diethylamino-ethylsulfanylmethyl)-cyclohexyl]-methyl-carbamic acid 4- chloro-phenyl ester, trans-{4-[2-(Allyl-methyl-amino)-ethylsulfanylmethyl]-cyclohexyl}-methyl-carbamic acid 4-chloro-phenyl ester, trans-{4-[3-(Allyl-methyl-amino)-propylsulfanylmethyl]-cyclohexyl}-methyl-carbamic acid 4-chloro-phenyl ester, trans-[4-(2-Dimethylamino-ethylsulfanylmethyl)-cyclohexyl]-methyl-carbamic acid 4- chloro-phenyl ester, trans-(4-{2-[Ethyl-(2-hydroxy-ethyl)-amino]-ethylsulfanylmethyl}-cyclohexyl)-methyl- carbamic acid 4-chloro-phenyl ester,

trans-Methyl-{4-[2-(methyl-propyl-amino)-ethylsulfanylmethyl]-cyclohexyl}-carbamic acid 4-chloro-phenyl ester, trans-{4-[3-(Allyl-methyl-amino)-prop-1-ynyl]-cyclohexyl}-methyl-carbamic acid 4- chloro-phenyl ester, trans-(4-{3- [Ethyl-(2-hydroxy-ethyl)-amino] -prop-1-ynyl}-cyclohexyl)-methyl-carbamic acid 4-chloro-phenyl ester, trans-(4-{3-[Ethyl-(2-hydroxy-ethyl)-amino]-propyl}-cyclohexyl)-methyl-carbamic acid 4-chloro-phenyl ester, trans-Methyl- {4-[4-(methyl-propyl-amino)-butoxy]-cyclohexyl}-carbamic acid 3,4- difluoro-phenyl ester,

trans-[4-[6-(Allyl-methyl-amino)-hexyloxy]-cyclohexyl]-methyl-sulfamic acid benzyl amide, trans-{4-[6-(Allyl-methyl-amino)-hexyloxy]-cyclohexyl}-methyl-sulfamic acid phenyl amide, trans-4-[({4-[6-(Allyl-methyl-amino)-hexyloxy]-cyclohexyl}-methyl-sulfamoyloxy)-

methyl]-benzoic acid methyl ester, trans-{4-[6-(Allyl-methyl-amino)-hexyloxy]-cyclohexyl}-methyl-sulfamic acid butyl amide, Fy

: trans-{4-[6-(Allyl-methyl-amino)-hexyloxy]-cyclohexyl}-methyl-sulfamic acid phenethyl amide,

‘ 35 trans-{4-[6-(Allyl-methyl-amino)-hexyloxy]-cyclohexyl}-methyl-sulfamic acid furan-2- ylmethyl amide, trans-({4-[6-(Allyl-methyl-amino)-hexyloxy]-cyclohexyl}-methyl-sulfonylamino)-acetic acid ethyl ester, trans-{4-[6-(Allyl-methyl-amino)-hexyloxy]-cyclohexyl}-methyl-sulfamic acid cyclopropyl amide, trans-{4-[6-(Allyl-methyl-amino)-hexyloxy]-cyclohexyl}-methyl-sulfamic acid 2,2,2- trifluoro-ethyl amide, trans-{4-[6-(Allyl-methyl-amino)-hexyloxy]-cyclohexyl}-methyl-sulfamic acid benzo[1,3]dioxol-5-ylmethyl amide,

‘ trans-{4-[6-(Allyl-methyl-amino)-hexyloxy]-cyclohexyl}-methyl-sulfamic acid 4- fluorobenzyl amide, trans-{4-[6-(Allyl-methyl-amino)-hexyloxy]-cyclohexyl}-methyl-sulfamic acid (4-chloro- phenyl)-amide,

trans-{4-[6-(Allyl-methyl-amino)-hexyloxy]-cyclohexyl}-methyl-sulfamic acid (4-fluoro- phenyl)-amide, trans-{4-[6-(Allyl-methyl-amino)-hexyloxy]-cyclohexyl}-methyl-sulfamic acid (4-bromo- phenyl)-amide, trans-{4-[6-(Allyl-methyl-amino)-hexyloxy]-cyclohexyl}-methyl-sulfamic acid (p-tolyl)-

amide, trans-{4-[6-(Allyl-methyl-amino)-hexyloxy]-cyclohexyl}-methyl-sulfamic acid (3,4- difluoro-phenyl)-amide, trans-{4-[6-(Allyl-methyl-amino)-hexyloxy]-cyclohexyl}-methyl-sulfamic acid (4- trifluoromethyl-phenyl)-amide,

trans-{4-[6-(Allyl-methyl-amino)-hexyloxy]-cyclohexyl}-methyl-sulfamic acid (3-fluoro- phenyl)-amide, trans-{4-[{6-(Allyl-methyl-amino)-hexyloxy]-cyclohexyl}-methyl-sulfamic acid (4-cyano- phenyl)-amide, trans-{4-[6-(Allyl-methyl-amino)-hexyloxy]-cyclohexyl}-methyl-sulfamic acid (2,4-

difluoro-phenyl)-amide, trans-{4-[6-(Allyl-methyl-amino)-hexyloxy]-cyclohexyl}-methyl-sulfamic acid (4- methoxy-phenyl)-amide, trans-{4-[6-(Allyl-methyl-amino)-hexyloxy]-cyclohexyl}-methyl-sulfamic acid (2,5- difluoro-phenyl)-amide,

trans-{4-[5-(Allyl-methyl-amino)-pentyloxy]-cyclohexyl}-methyl-sulfamic acid benzyl amide, trans-{4-[5-(Allyl-methyl-amino)-pentyloxy]-cyclohexyl}-methyl-sulfamic acid phenyl

- amide, trans-{4-[5-(Allyl-methyl-amino)-pentyloxy]-cyclohexyl}-methyl-sulfamic acid p-

. 35 chlorophenyl amide, trans-{4-[5-(Allyl-methyl-amino)-pentyloxy]-cyclohexyl}-methyl-sulfamic acid p- bromophenyl amide, trans-{4-[5-(Allyl-methyl-amino)-pentyloxy]-cyclohexyl}-methyl-sulfamic acid p- methylphenyl amide,

trans-{4-[5-(Allyl-methyl-amino)-pentyloxy]-cyclobexyl}-methyl-sulfamic acid p- triftuoromethylphenyl amide, trans-{4-[5-(Allyl-methyl-amino)-pentyloxy]-cyclohexyl}-methyl-sulfamic acid p- ’ cyanophenyl amide, trans-{4-[5-(Allyl-methyl-amino)-pentyloxy]-cyclohexyl}-methyl-sulfamic acid p- methoxyphenyl amide, trans-{4-[5-(Allyl-methyl-amino)-pentyloxy]-cyclohexyl}-methyl-sulfamic acid 3,4~ difluorophenyl amide, trans-{4-[5-(Allyl-methyl-amino)-pentyloxy]-cyclohexyl}-methyl-sulfamic acid 3-

fluorophenyl amide, trans-{4-[5-(Allyl-methyl-amino)-pentyloxy]-cyclohexyl}-methyl-sulfamic acid 2,4- difluorophenyl amide, trans-{4-[5-(Allyl-methyl-amino)-pentyloxy] -cyclohexyl}-methyl-sulfamic acid 2,5- difluorophenyl amide,

trans-{4-[3-(Allyl-methyl-amino)-propoxy]-cyclohexyl}-methyl-sulfamic acid phenyl amide, trans-{4-[3-(Allyl-methyl-amino)-propoxy]-cyclohexyl}-methyl-sulfamic acid 3,4- difluorophenyl amide, trans-{4-[3-(Allyl-methyl-amino)-propoxy]-cyclohexyl}-methyl-sulfamic acid 4-

chlorophenyl amide, trans-{4-[3-(Allyl-methyl-amino)-propoxy}-cyclohexyl}-methyl-sulfamic acid benzyl amide, trans-{4-[4-(Allyl-methyl-amino)-butoxy]-cyclohexyl}-methyl-sulfamic acid phenyl amide,

trans-{4-[4-(Allyl-methyl-amino)-butoxy]-cyclohexyl}-methyl-sulfamic acid 3-fluoro phenyl amide, trans-{4-[4-(Allyl-methyl-amino)-butoxy]-cyclohexyl}-methyl-sulfamic acid 3,4-difluoro phenyl amide, trans-{4-[4-(Allyl-methyl-amino)-butoxy] -cyclohexyl}-methyl-sulfamic acid 4-chloro phenyl amide, trans-{4-[4-(Allyl-methyl-amino)-butoxy]-cyclohexyl}-methyl-sulfamic acid benzyl amide,

’ trans-({4-[4-(Allyl-methyl-amino)-butoxy]-cyclohexyl}-methyl-sulfamoylamino)-acetic acid ethyl ester,

: 35 trans-{4-[7-(Allyl-methyl-amino)-heptyloxy]-cyclohexyl}-methyl-sulfamic acid phenyl amide, trans-{4-[7-(Allyl-methyl-amino)-heptyloxy] -cyclohexyl}-methyl-sulfamic acid 3-fluoro- phenyl amide, trans-{4-[7-(Allyl-methyl-amino)-heptyloxy]-cyclohexyl}-methyl-sulfamic acid 3,4-

difluoro-phenyl amide, trans-{4-[7-(Allyl-methyl-amino)-heptyloxy]-cyclohexyl}-methyl-sulfamic acid 4-chloro- phenyl amide, : trans-{4-(7-(Allyl-methyl-amino)-heptyloxy]-cyclohexyl}-methyl-sulfamic acid furan-2- ylmethyl amide, trans-{4-{7-(Allyl-methyl-amino)-heptyloxy]-cyclohexyl}-methyl-sulfamic acid benzyl amide, trans-({4-[7-(Allyl-methyl-amino)-heptyloxy]-cyclohexyl}-methyl-sulfamoyloxy)-acetic acid ethyl amide,

trans-1-{4-[6-(Allyl-methyl-amino)-hexyloxy]-cyclohexyl}-3-(2-bromo-4-fluoro-phenyl)- 1-methyl-thiourea, trans-1-{4-[6-(Allyl-methyl-amino)-hexyloxy]-cyclohexyl}-3-(4-bromo-2-methyl- phenyl)-1-methyl-thiourea, trans-1-{4-[6-( Allyl-methyl-amino)-hexyloxy]-cyclohexyl}-1-methyl-3-(4-

trifluoromethyl-phenyl)-thiourea, trans1-{4-[6- (Allyl-methyl-amino)-hexyloxy) -cyclohexyl}-3-(4-chloro-phenyl)-1-methyl- thiourea, trans1-{4-[6-(Allyl-methyl-amino)-hexyloxy]-cyclohexyl}-3-(4-methoxy-phenyl)-1- methyl-thiourea,

trans-1-{4-[6-(Allyl-methyl-amino)-hexyloxy]-cyclohexyl}-3-(4-cyano-phenyl)-1-methyl- thiourea, trans-1-{4-[6-(Allyl-methyl-amino)-hexyloxy]-cyclohexyl}- 1-methyl-3-(3-methyl-butyl)- thiourea, trans-1-{4-[6-(Allyl-methyl-amino)-hexyloxy]-cyclohexyl}-3-sec-butyl-1-methyl-thiourea,

trans-1-{4-[4-(Allyl-methyl-amino)-butoxy]-cyclohexyl}-1-methyl-3-(4-trifluoromethyl- phenyl)-thiourea, trans-1-{4-[4-(Allyl-methyl-amino)-butoxy]-cyclohexyl}-3-(4-cyano-phenyl)- 1-methyl- thiourea, trans-1-{4-[{4- (Allyl-methyl-amino)-butoxy]- cyclohexyl}-1-methyl-3-(3-methyl-butyl)-

thiourea, trans-1-{4-[7-(Allyl-methyl-amino)-heptyloxy]-cyclohexyl}-1-methyl-3-(4- trifluoromethyl-phenyl)-thiourea,

: trans-1-{4-[7-(Allyl-methyl-amino)-heptyloxy]-cyclohexyl}-3-(4-cyano-phenyl)-1- methyl-thiourea,

. 35 trans-1-{4-[7-(Allyl-methyl-amino)-heptyloxy]-cyclohexyl}-1-methyl-3-(3-methyl-butyl)- thiourea, trans-1-{4-[3-(Allyl-methyl-amino)-propoxy]-cyclohexyl}-1-methyl-3-(4-trifluoromethyl- phenyl)-thiourea, trans-[4-(6-Dimethylamino-hexyloxy)-cyclohexyl]-carbamic acid benzyl ester,

trans-[4-(5-Dimethylamino-pentyloxy)-cyclohexyl]-carbamic acid benzyl ester, trans-{4-[6-(Allyl-methyl-amino)-hexyloxy]-cyclohexyl}-carbamic acid benzyl ester, trans-N-{4-[5-(Allyl-methyl-amino)-pentyl]-cyclohexyl}-N-methyl-4-trifluoromethyl- ‘ benzenesulfonamide, trans-N-(4-{5-[Ethyl-(2-hydroxy-ethyl)-amino|-pentyl}-cyclohexyl) -N-methyl-4- ’ trifluoromethyl-benzenesulfonamide, and trans-{4-[4-(Allyl-methyl-amino)-butyl]-cyclohexyl}-methyl-carbamic acid 4-chloro- phenyl ester, and pharmaceutically acceptable salts thereof.

Other preferred compounds of general formula (I) are those selected from the group consisting of trans-N-[4-(3-Allylamino-propoxy)-cyclohexyl]-N-methyl-4-trifluoromethyl- benzenesulfonamide, trans-N-{4-[4-(Allyl-methyl-amino)-butoxy]-cyclohexyl}-N-ethyl-4-trifluoromethyl- benzenesulfonamide, trans-N-[4-(4-Dimethylamino-butoxy)-cyclohexyl]-N-ethyl-4-trifluoromethyl- benzenesulfonamide, trans-N-Ethyl-N-(4-{4-[(2-hydroxy-ethyl)-methyl-amino]-butoxy}-cyclohexyl)-4- trifluoromethyl-benzenesulfonamide, trans-N-Ethyl-N-(4-{4-[(2-methoxy-ethyl)-methyl-amino]-butoxy}-cyclohexyl)-4- trifluoromethyl-benzenesulfonamide, trans-N-Ethyl-N-(4-{4- [ethyl-(2-hydroxy-ethyl)-amino]-butoxy}-cyclohexyl)-4- trifluoromethyl-benzenesulfonamide, trans-N-Ethyl-N-(4-{4-[ethyl-(2-methoxy-ethyl)-amino]-butoxy}-cyclohexyl)-4- trifluoromethyl-benzenesulfonamide, trans-N-(4-{4-[Bis-(2-hydroxy-ethyl)-amino]-butoxy}- cyclohexyl) -N-ethyl-4- trifluoromethyl-benzenesulfonamide, trans-N- [4-(4-Diethylamino-butoxy)-cyclohexyl]-N-ethyl-4-trifluoromethyl- benzenesulfonamide, trans-N-{[4-(4-Allylamino-butoxy)-cyclohexyl]-N-ethyl-4-trifluoromethyl- benzenesulfonamide, - . trans-N-Ethyl-N-{4-(4-piperidin- 1-yl-butoxy)-cyclohexyl]-4-trifluoromethyl- benzenesulfonamide, . trans-N-Ethyl-N-{4-[4-(4-methyl-piperazin-1-yl)-butoxy]-cyclohexyl}-4-trifluoromethyl- benzenesulfonamide, trans-[4-(6-Dimethylamino-hexyloxy)-cyclohexyl]-carbamic acid benzyl ester, trans-[4-(5-Dimethylamino-pentyloxy)-cyclohexyl]-carbamic acid benzyl ester,

Trans-N-{4-[4-(2-Hydroxy-ethylamino)-butyl]-cyclohexyl}-N-methyl-4-trifluoromethyl-

benzenesulfonamide,

Trans-N-[4-(5-Ethylamino-pentyl)-cyclohexyl]-N-methyl-4-trifluoromethyl- benzenesulfonamide, trans- N-(4-{5-[Ethyl-(2-hydroxy-ethyl)-amino] -pentyl}-cyclohexyl)-N-methyl-4- trifluoromethyl-benzenesulfonamide N-oxide, : trans-N-(4-{5-[Ethyl-(2-fluoro-ethyl)-amino]-pentyl}-cyclohexyl)-N-methyl-4- trifluoromethyl-benzenesulfonamide, trans-4-Bromo-N-[4-(2-diisopropylamino-ethoxy)-cyclohexyl]-N-methyl- benzenesulfonamide,

Trans-4-Bromo-N-methyl-N-[4-(2-piperidin-1-yl-ethoxy)-cyclohexyl]- benzenesulfonamide,

Trans-4-Bromo-N-[4-(2-diethylamino-ethoxy)-cyclohexyl]-N-methyl- benzenesulfonamide, trans-4-Bromo-N-methyl-N-[4-(2-morpholin-4-yl-ethoxy)-cyclohexyl]- benzenesulfonamide, trans-4-Bromo-N-methyl-N-{4-(2-pyrrolidin- 1-yl-ethoxy)-cyclohexyl]- benzenesulfonamide,

Trans-N-[4-(3-Dimethylamino-3-methyl-butoxy)-cyclohexyl]-N-methyl-4- trifluoromethyl-benzenesulfonamide,

Trans-N-{4-[2-(1-Dimethylamino-cyclopropyl)-ethoxy]-cyclohexyl}-N-methyl-4- trifluoromethyl-benzenesulfonamide,

Trans-N-[4-(5-Diethylamino-5-methyl-hexyl)-cyclohexyl] -N-methyl-4-trifluoromethyl- benzenesulfonamide,

Trans-N-{4-[4-(1-Diethylamino-cyclopropyl)-butyl]-cyclohexyl}-N-methyl-4- trifluoromethyl-benzenesulfonamide, trans-N-[4-(4-Dimethylamino-pentyloxy)-cyclohexyl]-N-methyl-4-trifluoromethyl- benzenesulfonamide, trans-N-[4-(2-Diethylamino-ethoxy)-cyclohexyl]-N-methyl-4-trifluoromethyl- benzenesulfonamide, trans-N-Methyl-N-[4-(2-piperidin-1-yl-ethoxy)-cyclohexyl]-4-trifluoromethyl- benzenesulfonamide, trans-N- [4-(2-Diisopropylamino-ethoxy)-cyclohexyl]-N-methyl-4-trifluoromethyl- ’ benzenesulfonamide, trans-N-Methyl-N-[4-(2-pyrrolidin-1-yl-ethoxy)-cyclohexyl]-4-trifluoromethyl- : 35 benzenesulfonamide, trans-N-Methyl-N-[4-(2-morpholin-4-yl-ethoxy)-cyclohexyl]-4-trifluoromethyl- benzenesulfonamide, trans-N-Methyl-N-[4-(4-piperidin- 1-yl-pentyloxy)-cyclohexyl]-4-trifluoromethyl- benzenesulfonamide,

Trans-[4-(3-Dimethylamino-3-methyl-but-1-ynyl)-cyclohexyl] -methyl-carbamic acid tert-butyl ester, cis- N-(4-{5-[Ethyl-(2-hydroxy-ethyl)-amino]-pentyl}-cyclohexyl)-N-methyl-4- trifftuoromethyl-benzenesulfonamide, trans-(4-{4-[Ethyl-(2-hydroxy-ethyl)-amino]-butyl}-cyclohexyl)-methyl-carbamic acid 4-

chloro-phenyl ester, trans-{4- [4-(Allyl-methyl-amino)-butyl]-cyclohexyl}-methyl-carbamic acid 4- trifluoromethyl-phenyl ester, trans-(4-{4-[Ethyl-(2-hydroxy-ethyl)-amino]-butyl}-cyclohexyl)-methyl-carbamic acid 4-

trifluoromethyl-phenyl ester, trans-{4-[4-(Allyl-methyl-amino)-butyl]-cyclohexyl}-methyl-carbamic acid 4-bromo- phenyl ester, trans-(4-{4-[Ethyl- (2-hydroxy-ethyl)-amino]-butyl}-cyclohexyl)-methyl-carbamic acid 4- bromo-phenyl ester,

trans-Methyl-{4-[4-(methyl-propyl-amino)-butyl]-cyclohexyl}-carbamic acid 4-bromo- phenyl ester, trans-[4-(4-Diethylamino-butyl)-cyclohexyl}-methyl-carbamic acid 4-bromo-phenyl ester, trans-[4-(4-Dimethylamino-butyl)-cyclohexyl}-methyl-carbamic acid 4-bromo-phenyl ester, trans-Methyl-[4-(4-piperidin-1-yl-butyl)-cyclohexyl]-carbamic acid 4-bromo-phenyl ester, trans-Methyl-{4-[4-(4-methyl-piperazin-1-yl)-butyl}-cyclohexyl}-carbamic acid 4-bromo- phenyl ester,

trans-Methyl-[4-(4-morpholin-4-yl-butyl)-cyclohexyl]- carbamic acid 4-bromo-phenyl ester, trans-Methyl- [4-(4-thiomorpholin-4-yl-butyl)-cyclohexyl]-carbamic acid 4-bromo- phenyl ester, trans-Methyl-[4-(4-piperidin-1-yl-butyl)-cyclohexyl]-carbamic acid 4-trifluoromethyl-

phenyl ester, trans-[4-(4-Dimethylamino-butyl)-cyclohexyl]-methyl-carbamic acid 4-trifluoromethyi- phenyl ester,

: trans-Methyl- [4-(4-thiomorpholin-4-yl-butyl)-cyclohexyl]-carbamic acid 4- trifluoromethyl-phenyl ester,

, 35 trans-Methyl-{4-[4-(methyl-propyl-amino)-butyl]-cyclohexyl}-carbamic acid 4- trifluoromethyl-phenyl ester, trans-N-{4-[4-(Allyl-methyl-amino)-butyl]-cyclohexyl}-N-methyl-4-trifluoromethyl- benzenesulfonamide, trans-N-(4-{4-[Ethyl-(2-hydroxy-ethyl)-amino]-butyl}-cyclohexyl)-N-methyl-4-

trifluoromethyl-benzenesulfonamide, trans-N-Methyl-N- [4-(4-piperidin-1-yl-butyl)- cyclohexyl] -4-trifluoromethyl- benzenesulfonamide, ‘ trans-N-[4-(4-Dimethylamino-butyl)-cyclohexyl]-N-methyl-4-trifluoromethyl- benzenesulfonamide, : trans-N-Methyl-N-{4-[4-(methyl-propyl-amino)-butyl] -cyclohexyl}-4-trifluoromethyl- benzenesulfonamide, trans-N-(4-{4-[Bis-(2-hydroxy-ethyl)-amino] -butyl}-cyclohexyl)-N-methyl-4- trifluoromethyl-benzenesulfonamide, trans-{4-[5-(Allyl-methyl-amino)-pentyl]-cyclohexyl}-methyl-carbamic acid 2,4-difluoro- phenyl ester, trans-(4-{5-{Ethyl-(2-hydroxy-ethyl)-amino]-pentyl}-cyclohexyl)-methyl-carbamic acid 2,4-difluoro-phenyl ester, trans-(4-{5-[Ethyl-(2-hydroxy-ethyl)-amino]-pentyl}-cyclohexyl)-methyl-carbamic acid 4-chloro-phenyl ester, trans-Methyl-{4-[5-(methyl-propyl-amino)-pentyl]-cyclohexyl}-carbamic acid 4-chloro- phenyl ester, trans-{4-(5-Dimethylamino-pentyl)-cyclohexyl]-methyl-carbamic acid 4-chloro-phenyl ester, trans-Methyl-[4-(5-piperidin- 1-yl-pentyl)-cyclohexyl]-carbamic acid 4-chloro-phenyl ester, trans-Methyl-{4-[5-(4-methyl-piperazin-1-yl)-pentyl]-cyclohexyl}-carbamic acid 4- chloro-phenyl ester, trans-{4-[5-(Cyclopropyl-methyl-amino)-pentyl]-cyclohexyl}-methyl-carbamic acid 4- chloro-phenyl ester, trans-N- [4-(5-Diethylamino-pentyl)-cyclohexyl]-N-methyl-4-trifluoromethyl- benzenesulfonamide, trans-N-(4-{5-[Bis-(2-hydroxy-ethyl)-amino]-pentyl}-cyclohexyl)-N-methyl-4- trifluoromethyl-benzenesulfonamide, (cis){4-[5-(Allyl-methyl-amino)-pentyl]-cyclohexyl}-methyl-carbamic acid 4- trifluoromethyl-phenyl ester, trans-{4-{5-(Allylamino)-pentyl]-cyclohexyl}-methyl-carbamic acid 4-trifluoromethyl- . phenyl ester,

Trans-Methyl-[4-(5-methylamino-pentyl)-cyclohexyl]-carbamic acid 4-trifluoromethyl- . 35 phenyl ester, trans-N-[4-(5-Allylamino-pentyl)-cyclohexyl]-N-methyl-4-trifluoromethyl- benzenesulfonamide, trans-N-{4-[5-(2-Hydroxy-1,1-dimethyl-ethylamino)-pentyl]-cyclohexyl}-N-methyl-4- trifluoromethyl-benzenesulfonamide,

trans-N-Methyl-N-[4-(5-methylamino-pentyl)-cyclohexyl]-4-trifluoromethyl- benzenesulfonamide, (trans)-[4-(5-Dimethylamino-pent-1-ynyl)-cyclohexyl]-methyl-carbamic acid 4-chloro- phenyl ester,

Trans-Methyl-{4-[5-(methyl-propyl-amino)-pent-1-ynyl}-cyclohexyl}-carbamic acid 4- : chloro-phenyl ester,

Trans-(4-{5-[Ethyl-(2-hydroxy-ethyl)-amino]-pent- 1-ynyl}-cyclohexyl)-methyl-carbamic acid 4-chloro-phentyl ester,

Trans-N-(4-{3-[Bis-(2-hydroxy-ethyl)-amino]-prop-1-ynyl}-cyclohexyl)-N-methyl-4- trifluoromethyl-benzenesulfonamide,

Trans-N-(4-{3-[Ethyl-(2-hydroxy-ethyl)-amino]-prop-1-ynyl}-cyclohexyl)-N-methyl-4- trifluoromethyl-benzenesulfonamide, trans-[4-(4-Dimethylamino-butoxy)-cyclohexyl]-methyl-carbamic acid isobutyl ester, trans-(4-{4-{Ethyl-(2-hydroxy-ethyl)-amino}-butoxy}-cyclohexyl)-methyl-carbamic acid isobutyl ester, trans-[4-(4-Diethylamino-butoxy)-cyclohexyl] -methyl-carbamic acid isobutyl ester, trans-[4-(4-Azetidin-1-yl-butoxy)-cyclohexyl]-methyl-carbamic acid isobutyl ester, trans-Methyl-[4-(4-morpholin-4-yl-butoxy)-cyclohexyl] -carbamic acid isobutyl ester, trans-Methyl-[4-(4-pyrrolidin-1-yl-butoxy)-cyclohexyl]-carbamic acid isobutyl ester, trans-(4-{4-[Ethyl-(2-methoxy-ethyl)-amino]-butoxy}-cyclohexyl)-methyl-carbamic acid isobutyl ester, trans-Methyl-{4-[4-(methyl-propyl-amino)-butoxy]-cyclohexyl}-carbamic acid isobutyl ester, trans-(4-{4-[Bis-(2-hydroxy-ethyl)-amino}-butoxy}-cyclohexyl)-methyl-carbamic acid isobutyl ester, trans-{4-[4-(Cyclopropylmethyl-methyl-amino)-butoxy]-cyclohexyl}-methyl-carbamic acid isobutyl ester,

Trans-N-(4-{3-[Bis-(2-hydroxy-ethyl)-amino]-propyl}-cyclohexyl)-N-methyl-4- trifluoromethyl-benzenesulfonamide,

Trans-N-(4-{3-[Ethyl-(2-hydroxy-ethyl)-amino]-propyl}-cyclohexyl)-N-methyl-4- trifluoromethyl-benzenesulfonamide,

Trans-[4-(3-Dimethylamino-prop-1-ynyl)-cyclohexyl]-methyl-carbamic acid 4-chloro- ’ phenyl ester,

Trans-(4-{3-[Bis-(2-hydroxy-ethyl)-amino]-prop-1-ynyl}-cyclohexyl)-methyl-carbamic : 35 acid 4-trifluoromethyl-phenyl ester,

Trans-Methyl-[4-(3-piperidin-1-yl-prop-1-ynyl)-cyclohexyl]-carbamic acid 4-chloro- phenyl ester,

Trans-[4-(3-Dimethylamino-prop- 1-ynyl)-cyclohexyl]-methyl-carbamic acid 4- trifluoromethyl-phenyl ester,

Trans-Methyl- {4-[3-(methyl-propyl-amino)-prop-1-ynyl]-cyclohexyl}-carbamic acid 4- trifluoromethyl-phenyl ester,

Trans-Methyl- [4~(3-piperidin-1-yl-prop- 1-ynyl)-cyclohexyl] -carbamic acid 4- ) trifluoromethyl-pheny] ester, trans-{4-[4-(Allyl-methyl-amino)-butoxy]-cyclohexyl}-methyl-carbamic acid 2,4- ’ difluoro-phenyl ester, trans-[4-(4-Dimethylamino-butoxy)-cyclohexyl}-methyl-carbamic acid 2,4-difluoro- phenyl ester, trans-(4-{4-[Ethyl-(2-hydroxy-ethyl)-amino]-butoxy}-cyclohexyl) -methyl-carbamic acid 2,4-difluoro-phenyl ester, trans-Methyl-[4-(4-morpholin-4-yl-butoxy)-cyclohexyl]-carbamic acid 2,4-difluoro- phenyl ester, trans-(4-{4-[Ethyl-(2-methoxy-ethyl)-amino]-butoxy}-cyclohexyl)-methyl-carbamic acid 2,4-difluoro-phenyl ester, trans-Methyl-{4-[4-(methyl-propyl-amino)-butoxy]-cyclohexyl}-carbamic acid 2,4- difluoro-phenyl ester, trans-3,4-Difluoro-N-methyl-N-{4-[4-(methyl-propyl-amino)-butoxy] -cyclohexyl}- : benzenesulfonamide, trans-N-(4-{4-[Ethyl-(2-hydroxy-ethyl)-amino]-butoxy}-cyclohexyl)-3,4-difluoro-N- methyl-benzenesulfonamide, trans-2,4-Difluoro-N-methyl-N-{4-{4-(methyl-propyl-amino)-butoxy]-cyclohexyl}- benzenesulfonamide, trans-N-(4-{4-[Ethyl-(2-hydroxy-ethyl)-amino]-butoxy}-cyclohexyl)-2,4-difluoro-N- methyl-benzenesulfonamide,

Trans-4-Dimethylamino-N-[4-(4-dimethylamino-butoxy)-cyclohexyl]-3-fluoro-N- methyl-benzenesulfonamide,

Trans-4-Dimethylamino-N-[4-(4-dimethylamino-butoxy)-cyclohexyl]-2-fluoro-N- methyl-benzenesulfonamide,

Trans-Methyl-{4-[3-(methyl-propyl-amino)-prop-1-ynyl}-cyclohexyl}-carbamic acid 4- chloro-phenyl ester,

Trans-Methyl-{4-[3-(methyl-propyl-amino)-prop-1-ynyl]-cyclohexyl}-carbamic acid 4- chloro-phenyl ester, : Trans-[4-(3-Dimethylamino-propyl)-cyclohexyl]-methyl-carbamic acid 4-chloro-phenyl ester, : 35 Trans-(4-{3-[Ethyl-(2-hydroxy-ethyl)-amino]-propyl}-cyclohexyl)-methyl-carbamic acid 4-trifluoromethyl-phenyl ester,

Trans-(4-{3-[Bis-(2-hydroxy-ethyl)-amino]-propyl}-cyclohexyl)-methyl-carbamic acid 4- trifluoromethyl-phenyl ester,

Trans-Methyl-{4-(3-(methyl-propyl-amino)-propyl]-cyclohexyl}-carbamic acid 4-chloro-

phenyl ester,

Trans-(4-{4-[Ethyl-(2-hydroxy-ethyl)-amino]-but- 1-ynyl}-cyclohexyl)-methyl- carbamic acid 4-chloro-phenyl ester, ’ Trans-N-(4-{5-[Ethyl-(2-hydroxy-ethyl)-amino]-pent- 1-ynyl}-cyclohexyl)-N-methyl-4- trifluoromethyl-benzenesulfonamide, : ' Trans-N-Methyl-N-{4-[5-(methyl-propyl-amino)-pent-1-ynyl]-cyclohexyl}-4- trifluoromethyl-benzenesulfonamide,

Trans-N-[4-(4-Dimethylamino-but-1-ynyl)-cyclohexyl]-N-methyl-4-trifluoromethyl- benzenesulfonamide,

Trans-N-Methyl-N-{4-[4-(methyl-propyl-amino)-but-1-ynyl] -cyclohexyl}-4- trifluoromethyl-benzenesulfonamide,

Trans-N-(4-{4-[Ethyl-(2-hydroxy-ethyl)-amino]-but-1-ynyl}-cyclohexyl)-N-methyl-4- trifluoromethyl-benzenesulfonamide,

Trans-Methyl-{4-[3-(methyl-propyl-amino)-prop-1-ynyl]-cyclohexyl}-carbamic acid 4- methoxy-phenyl ester,

Trans-Methyl-{4-[3-(methyl-propyl-amino)-prop-1-ynyl]-cyclohexyl}-carbamic acid p- tolyl ester,

Trans-(4-{3-[Ethyl-(2-methoxy-ethyl)-amino]-prop- 1-ynyl}-cyclohexyl)-methyl-carbamic acid 4-chloro-phenyl ester, trans-{4-[5-(Allyl-methyl-amino)-pentyl]-cyclohexyl}-methyl-carbamic acid 4- trifluoromethyl-phenyl ester N-oxide,

Trans-N-Methyl-N-{4-[3-(methyl-propyl-amino)-prop-1-ynyl}-cyclohexyl}-4- trifluoromethyl-benzenesulfonamide,

Trans-N-[4-(3-Dimethylamino-prop-1-ynyl)-cyclohexyl]-N-methyl-4-trifluoromethyl- benzenesulfonamide,

Trans-N-(4-{3-[Ethyl-(2-methoxy-ethyl)-amino]-prop-1-ynyl}-cyclohexyl)-N-methyl-4- trifluoromethyl-benzenesulfonamide,

Trans-Methyl-{4-[4-(methyl-propyl-amino)-but-1-ynyl]-cyclohexyl}-carbamic acid 4- trifluoromethyl-phenyl ester, Trans-[4-(4-Dimethylamino-but-1-ynyl)-cyclohexyl]-methyl-carbamic acid 4- trifluoromethyl-phenyl ester,

Trans-{4-[4-(Allyl-methyl-amino)-but-1-ynyl]-cyclohexyl}-methyl-carbamic acid 4- ’ trifluoromethyl-phenyl ester,

Trans-(4-{4-[Ethyl-(2-hydroxy-ethyl)-amino]-but-1-ynyl}-cyclohexyl)-methyl-carbamic acid 4-trifluoromethyl-phenyl ester,

Trans-Methyl-{4-[4-(methyl-propyl-amino)-but- 1-ynyl]-cyclohexyl}-carbamic acid 4- chloro-phenyl ester,

Trans-[4-(4-Dimethylamino-but-1-ynyl)-cyclohexyl]-methyl-carbamic acid 4-chloro- phenyl ester,

Trans-{4-[4-(Allyl-methyl-amino)-but-1-ynyl]-cyclohexyl}-methyl-carbamic acid 4- chloro-phenyl ester, trans-(1E)-N-Methyl-N-{4-[3-(methyl-propyl-amino)-propenyl]-cyclohexyl}-4- : trifluoromethyl-benzenesulfonamide, trans-(1E)-N-[4-(3-Dimethylamino-propenyl)-cyclohexyl]-N-methyl-4-trifluoromethyl- : benzenesulfonamide, trans-(1E)-N-{4-[3-(Allyl-methyl-amino)-propenyl]-cyclohexyl}-N-methyl-4- trifluoromethyl-benzenesulfonamide, trans-(1E)-N-(4-{3-[Ethyl-(2-hydroxy-ethyl)-amino]-propenyl}-cyclohexyl)-N-methyl-4- trifluoromethyl-benzenesulfonamide, trans-N-Methyl-4-nitro-N-[4-(4-piperidin-1-yl-butoxy)-cyclohexyl]- benzenesulfonamide, trans-N-(4-{4-[Ethyl-(2-methoxy-ethyl)-amino]-butoxy}-cyclohexyl)-N-methyl-4-nitro- benzenesulfonamide, trans-N-[4-(4-Dimethylamino-butoxy)-cyclohexyl]-N-methyl-4-nitro- benzenesulfonamide, trans-N-{4-[4-(Allyl-methyl-amino)-butoxy]-cyclohexyl}-N-methyl-4-nitro- benzenesulfonamide, trans-N-(4-{4-[Ethyl-(2-hydroxy-ethyl)-amino]-butoxy}-cyclohexyl)-N-methyl-4-nitro- benzenesulfonamide, trans-N-{4-[4-(4-Hydroxy-piperidin-1-yl)-butoxy]-cyclohexyl}-N-methyl-4-nitro- benzenesulfonamide,

Trans-Methyl-{4-[3-(methyl-propyl-amino)-propyl]-cyclohexyl}-carbamic acid p-tolyl ester,

Trans-4-Amino-N-methyl-N-{4-[3-(methyl-propyl-amino)-prop-1-ynyl] -cyclohexyl}- benzenesulfonamide,

Trans-Methyl-{4-[3-(methyl-propyl-amino)-propenyl]-cyclohexyl}-carbamic acid 4- trifluoromethyl-phenyl ester,

Trans-Methyl-{4-[3-(methyl-propyl-amino)-propenyl]-cyclohexyl}-carbamic acid 4- chloro-phenyl ester, trans-(1E)-(4-{3- [Ethyl-(2-methoxy-ethyl)-amino]-propenyl}-cyclohexyl)-methyl- carbamic acid 4-chloro-phenyl ester, Co ) trans-(1E)-(4-{3-[Ethyl-(2-hydroxy-ethyl)-amino]-propenyl}-cyclohexyl)-methyl- carbamic acid 4-chloro-phenyl ester, ; 35 Trans-4-Chloro-N-methyl-N-{4-[3-(methyl-propyl-amino)-prop-1-ynyl]-cyclohexyl}- benzamide,

Trans-3-(4-Chloro-phenyl)- 1-methyl- 1-{4-3-(methyl-propyl-amino)-prop-1-ynyl]- cyclohexyl}-urea,

Trans-4-Chloro-N-(4-{3-[ethyl- (2-hydroxy-ethyl)-amino]-prop-1-ynyl}-cyclohexyl)-N-

Claims

Claims

1. Compounds of formula (I) A°

N. A A w-a" AND OPN oY. (CH), (CF © A wherein U is O or a lone pair, Vv 1s O, §, -CH,-, -CH=CH-, or -C=C-, Ww is CO, COO, CONR', CSO, CSNR', SO, or SO.NR', mandn independently from each other are 0 to 7 and m+n is 0 to 7, with the proviso thatmisnot0if VisOorS, A is H, lower-alkyl, hydroxy-lower-alkyl, or lower-alkenyl, A? is lower-alkyl, cycloalkyl, cycloalkyl-lower-alkyl, or lower-alkenyl, optionally substituted by R, A’and A* are hydrogen or lower-alkyl, or A'and A? or A! and A’ are bonded to each other to form a ring and - A'- A% or - Al- A3- are lower-alkylene or lower-alkenylene, optionally substituted by R?, in which one -CH- group of -A'- A> or -A'-A’- can optionally be replaced by NR?, S, or O, or A’ and A* are bonded to each other to form a ring together with the carbon atom to which they are attached and AAs -(CHy_);-5- which can optionally be mono- or multiply-substituted by lower-alkyl, A® is H, lower-alkyl, lower-alkenyl, or aryl-lower-alkyl, ’ AS is lower-alkyl, cycloalkyl, aryl, aryl-lower-alkyl, heteroaryl, heteroaryl-lower- alkyl, lower-alkoxy-carbonyl-lower-alkyl, R? is hydroxy, hydroxy-lower-alkyl, lower-alkoxy, lower-alkoxycarbonyl, N(R*R?), or thio-lower-alkoxy,

R', R?, R* and R’® independently from each other are hydrogen or lower-alkyl, and pharmaceutically acceptable salts and/or pharmaceutically acceptable esters thereof.

) 2. Compounds according to claim 1, wherein A> and A* are not bonded to each other to form a ring together with the carbon atom to which they are attached.

3. Compounds according to any of claims 1 to 2, characterised by formula (Ia) A°

N. 3 4 W-A° A A Vv R AN pe INA ul (CH), (CHa; (Ta) A wherein U, V, W, m,n, A, A%, A%, A*, A’ and A’ have the significances given in any of claims 1 to 2.

4. Compounds according to any of claims 1 to 3, wherein U is a lone pair.

5. Compounds according to any of claims 1 to 4, wherein V is O.

6. Compounds according to any of claims 1 to 4, wherein V is-CH-.

7. Compounds according to any of claims 1 to 4, wherein V is -C=C-.

8. Compounds according to any of claims 1 to 4, wherein V is -C=C-.

9. Compounds according to any of claims 1 to 8, wherein W is CO, COO, CONR', CSNR', SO; or SO,NR' and R' is hydrogen.

10. Compounds according to any of claims 1 to 9, wherein W is COO or SO,.

11. Compounds according to any of claims 1 to 10, wherein n is 0.

12. Compounds according to any of claims 1 to 10, wherein n is 1.

13. Compounds according to any of claims 1 to 12, wherein mis 1 to 6.

14. Compounds according to any of claims 1 to 12, wherein m is 0 and V is -C=C- or -C=C-

15. Compounds according to any of claims 1 to 14, wherein Al is H, methyl, ethyl, isopropyl, 2-hydroxy-ethyl, or 2-propenyl. . 16. Compounds according to any of claims 1 to 15, wherein A? is lower-alky], cycloalkyl-lower-alkyl, or lower-alkenyl, optionally substituted with R%, wherein R is hydroxy, methoxy, or ethoxycarbonyl.

17. Compounds according to any of claims 1 to 16, wherein A? is methyl, ethyl, 2- hydroxy-ethyl, 2-propenyl, propyl or isopropyl.

18. Compounds according to any of claims 1 to 14, wherein A' and A? are bonded to each other to form a ring and -A'-A%- is lower-alkylene or lower-alkenylene, optionally substituted by R?, in which one -CH,- group of -A'-A’- can optionally be replaced by NR?, S, or O, wherein R? and R® are as defined in claim 1.

19. Compounds according to claim 18, wherein Al and A? are bonded to each other to form a ring and -A'-A’- is lower-alkylene or lower-alkenylene, optionally substituted by R?, in which one -CHa- group of -A'-A’- can optionally be replaced by O, wherein R? is hydroxy or 2-hydroxyethyl.

20. Compounds according to claim 19, wherein A' and A? are bonded to each other to form a ring and -AL-A% is -(CH,)s-.

21. Compounds according to any of claims 1 to 20, wherein A? is hydrogen.

22. Compounds according to any of claims 1 to 21, wherein A* is hydrogen.

23. Compounds according to any of claims 1 to 19, wherein A® and A* are bonded to each other to form a cyclopropyl-ring together with the carbon atom to which they are attached and -A>-A*%- is -(CH,),-.

24. Compounds according to any of claims 1 to 23, wherein A® is H, lower-alkyl, lower-alkenyl, or benzyl optionally substituted with halogen. : 25 25. Compounds according to any of claims 1 to 24, wherein A® is methyl or ethyl. . 26. Compounds according to any of claims 1 to 25, wherein A® is lower-alkyl, cycloalkyl, phenyl, naphthyl, phenyl-lower-alkyl, pyridyl, indolyl, indolinyl, thienyl, thienyl-methylene, furyl-methylene, benzodioxyl, chinolyl, isoxazolyl, or imidazolyl, optionally substituted by one or more substituents selected from the group consisting of lower-alkyl, lower-alkoxy, lower-alkylcarbonyl, lower-alkoxycarbonyl, fluorine, chlorine,

bromine, CN, CFs, NO,, or N(R,R”), wherein R® and R’ independently from each other are hydrogen or lower-alkyl. : 27. Compounds according to any of claims 1 to 26, wherein A® is phenyl optionally substituted by one or more substituents selected from the group consisting of fluorine, chlorine, bromine, and CFs.

28. Compounds according to any of claims 1 to 27, wherein A® is 4-chloro-phenyl], 4-bromo-phenyl, or 4-trifluoromethyl-phenyl.

29. A compound according to any of claims 1 to 28, selected from the group consisting of trans-{4-[6-(Allyl-methyl-amino)-hexyloxy]-cyclohexyl}-methyl-carbamic acid 4-chloro- phenyl ester, trans-{4-[4-(Allyl-methyl-amino)-butoxy]-cyclohexyl}-methyl-carbamic acid 4- trifluoromethyl-phenyl ester, trans-N- [4-(6-Diethylamino-hexyloxy)-cyclohexyl]-N-methyl-4-trifluoromethyl- benzenesulfonamide, trans-{4-[4-(Allyl-methyl-amino)-butoxy]-cyclohexyl}-methyl-carbamic acid 4-chloro- phenyl ester, trans-{4-[2-(Allyl-methyl-amino)-ethylsulfanylmethyl]-cyclohexyl}-methyl- carbamic acid 4-chloro-phenyl ester, trans-{4-[5-(Allyl-methyl-amino)-pentyl]-cyclohexyl}-methyl-carbamic acid 4-chloro- phenyl ester, trans-(4-{4-[Ethyl-(2-hydroxy-ethyl)-amino}-butoxy}-cyclohexyl)-methyl-carbamic acid 4-trifluoromethyl-phenyl ester, trans-N-[4-(3-Allylamino-propoxy)-cyclohexyl]-N-methyl-4-trifluoromethyl- benzenesulfonamide, trans-{4-[5-(Allyl-methyl-amino)-pentyl]-cyclohexyl}-methyl-carbamic acid 4- trifluoromethyl-phenyl ester, trans-(4-{5-[ Ethyl-(2-hydroxy-ethyl)-amino]-pentyl}-cyclohexyl)-methyl-carbamic acid

. 4-trifluoromethyl-phenyl ester, trans-(4-{5-[Ethyl-(2-hydroxy-ethyl)-amino]-pentyl}-cyclohexyl)-methyl-carbamic acid 3 4-bromo-phenyl ester, trans-N-(4-{5-[Ethyl-(2-hydroxy-ethyl)-amino]-pentyl}-cyclohexyl)-N-methyl-4- trifluoromethyl-benzenesulfonamide, trans-[4-(4-Dimethylamino-butoxy)-cyclohexyl]-methyl-carbamic acid 4-trifluoromethyl- phenyl ester,

trans-{4-[5-(Allyl-methyl-amino)-pentyl]-cyclohexyl}-methyl-carbamic acid 4-bromo- phenyl ester, trans-{4-[3-(Allyl-methyl-amino)-prop-1-ynyl]-cyclohexyl}-methyl-carbamic acid 4- ) chloro-phenyl ester, trans-N-{4-[5-(Allyl-methyl-amino)-pentyl]-cyclohexyl}-N-methyl-4-trifluoromethyl- benzenesulfonamide, trans-(4-{3-[Ethyl-(2-hydroxy-ethyl)-amino]-propyl}-cyclohexyl)-methyl-carbamic acid 4-chloro-phenyl ester, and trans- {4-[4-(Allyl-methyl-amino)-butyl]-cyclohexyl}-methyl-carbamic acid 4-chloro- phenyl ester, and pharmaceutically acceptable salts thereof.

30. A compound according to any of claims 1 to 29, selected from the group consisting of Trans-N-[4-(4-Dimethylamino-but-1-ynyl)-cyclohexyl]-N-methyl-4-trifluoromethyl- benzenesulfonamide, trans-Methyl-[4-(5-piperidin-1-yl-pentyl)-cyclohexyl]-carbamic acid 4-chloro-phenyl ester. Trans-Methyl-[4-(5-methylamino-pentyl)-cyclohexyl]-carbamic acid 4-trifluoromethyl- phenyl ester, Trans-(4-{5-[Ethyl-(2-hydroxy-ethyl)-amino]-pent-1-ynyl}-cyclohexyl)-methyl-carbamic acid 4-chloro-pheny! ester, trans-N-Ethyl-N-(4-{4-[(2-hydroxy-ethyl)-methyl-amino]-butoxy}-cyclohexyl)-4- trifluoromethyl-benzenesulfonamide, trans-(1E)-N-(4-{3-[Ethyl-(2-hydroxy-ethyl)-amino]-propenyl}-cyclohexyl)-N-methyl-4- trifluoromethyl-benzenesulfonamide, Trans-4-Bromo-N-[4-(2-diisopropylamino-ethoxy)-cyclohexyl}-N-methyl- benzenesulfonamide, trans-Methyl-[4-(4-piperidin- 1-yl-butyl)-cyclohexyl]- carbamic acid 4-bromo-phenyl ester, trans-N-Methyl-N-[4-(4-piperidin-1-yl-butyl)-cyclohexyl]-4-trifluoromethyl- benzenesulfonamide, - trans-N-(4-{4-[Bis-(2-hydroxy-ethyl)-amino]-butoxy}-cyclohexyl)-N-ethyl-4- trifluoromethyl-benzenesulfonamide, Trans-4-Bromo-N-methyl-N-{4-(2-piperidin-1-yl-ethoxy)-cyclohexyl]- benzenesulfonamide, trans-N-[4-(4-Dimethylamino-butoxy)-cyclohexyl] -N-ethyl-4-trifluoromethyl-

benzenesulfonamide, Trans-Methyl-{4-[3-(methyl-propyl-amino)-prop-1-ynyl]-cyclohexyl}-carbamic acid 4- chloro-phenyl ester, : trans-(1E)-N-Methyl-N-{4-[3-(methy!l-propyl-amino)-propenyl]-cyclohexyl}-4- trifluoromethyl-benzenesulfonamide, ’ Trans-N-(4-{4-[Ethyl-(2-hydroxy-ethyl)-amino]-but-1-ynyl}-cyclohexyl)-N-methyl-4- trifluoromethyl-benzenesulfonamide, Trans-N-Methyl-N-{4-[4-(methyl-propyl-amino)-but-1-ynyl]-cyclohexyl}-4- trifluoromethyl-benzenesulfonamide, and Trans-N-{4-[2-(1-Dimethylamino-cyclopropyl)-ethoxy]-cyclohexyl}-N-methyl-4- trifluoromethyl-benzenesulfonamide, and pharmaceutically acceptable salts thereof.

31. A process for the manufacture of compounds according to any of claims 1 to 30, which process comprises reacting a compound of formula (II) A° yA (IT) wherein A’ has the significance given in claim 1, ya is a group (A',A%)N-C(A%AY)-(CH2)m-V-(CHa), or HO-(CHy),,, wherein A', AZ, A’ A* V, m and n have the significances given in claim 1, with CISO,-A%, CICOO-A®, CICSO-A®, OCN-A®, SCN-A®, HOOC-A®, or CISO:NR'-A®, wherein A® has the significance given in claim 1.

32. Compounds according to any of claims 1 to 30 when manufactured by a process according to claim 31.

33. Pharmaceutical compositions comprising a compound according to any of . 25 claims 1 to 30 and a pharmaceutically acceptable carrier and/or adjuvant.

34. Compounds according to any of claims 1 to 30 for use as therapeutic active substances.

-218- PCT/EP01/09174 : 35. Compounds according to any of claims 1 to 30 for use as active substances in a method for the treatment and/or prophylaxis of diseases which are associated with OSC.

36. A method for the prophylaxis of diseases which are associated with OSC such as hypercholesterolemia, hyperlipemia, arteriosclerosis, vascular diseases, mycoses, parasite infections, gallstones, tumors and/or hyperproliferative disorders, and/or prophylaxis of impaired glucose tolerance and diabetes, which method comprises administering a compound according to any of claims 1 to 30 to a human being or animal.

37. The use of compounds according to any of claims 1 to 30 for the treatment and/or prophylaxis of diseases which are associated with OSC.

38. The use of compounds according to any of claims 1 to 30 for the treatment and/or prophylaxis of hypercholesterolemia, hyperlipemia, arteriosclerosis, vascular diseases, mycoses, parasite infections, gallstones, tumors and/or hyperproliferative disorders, and/or treatment and/or prophylaxis of impaired glucose tolerance, and diabetes.

39. The use of compounds according to any of claims 1 to 30 for the preparation of medicaments for the treatment and/or prophylaxis of diseases which are associated with OSC.

40. The use of compounds according to any of claims 1 to 30 for the preparation of medicaments for the treatment and/or prophylaxis of hypercholesterolemia, hyperlipemia, arteriosclerosis, vascular diseases, mycoses, parasite infections, gallstones, tumors and/or hyperproliferative disorders, and/or treatment and/or prophylaxis of impaired glucose tolerance and diabetes.

41. Use of a compound according to any of claims 1 to 30 in the manufacture of a preparation for use in treating the human or animal body. AMENDED SHEET

219- PCT/EP01/09174 : 42. A substance or composition for use in a method of treatment, said substance or composition comprising a compound according to any of claims 1 to 30, and said method comprising administering said substance or composition.

43. A substance or composition for use in a method for the treatment and/or prophylaxis of hypercholesterolemia, hyperlipemia, arteriosclerosis, vascular diseases, mycoses, parasite infections, gallstones, tumors and/or hyperproliferative disorders, and/or treatment and/or prophylaxis of impaired glucose tolerance and diabetes, said substance or composition comprising a compound according to any of claims 1 to 30, and said method comprising administering said substance or composition to a human being or animal.

44. The novel compounds, processes and methods as well as the use of such compounds substantially as described hereinbefore.

45. A compound according to any one of claims 1 to 30, 32, 34 or 35, substantially as herein described and illustrated.

46. A process according to claim 31, substantially as herein described and illustrated.

47. A composition according to claim 33, substantially as herein described and illustrated.

48. Use according to any one of claims 37 to 41, substantially as herein described and illustrated.

49. A method according to claim 36, substantially as herein described and illustrated.

50. A substance or composition for use in a method of treatment or prevention according to any one of claims 35, 42, or 43, substantially as herein described and illustrated. AMENDED SHEET

-220- PCT/EP01/09174 N 51. A new compound, a new process for preparing a compound, a new composition, a new use of a compound as claimed in any one of claims 1 to 30, a new non-therapeutic method of treatment, or a substance or composition for a new use in a method of treatment or prevention, substantially as herein described.

AMENDED SHEET